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Introducon 
I. Human diseases models 
Model organisms such as the fruit ﬂy, nematodes, bacteria, yeast, zebra ﬁsh or ro-
dents and other large animal models have been the focus of much of the biological 
research of the last 150 years.  The construcon of theorecal and empirical systems 
is a fundamental method of scienﬁc research. These systems, or models, are simpli-
ﬁed representaons of the phenomenon under study, which are parcularly useful 
when the manipulaons that can be done on the ‘real’ phenomenon are limited for 
technical or ethical reasons. In few areas of science this is more obvious than in re-
search on human biological phenomena.  
It is generally accepted that primive medicine arose by trial and error of treatments 
for diﬀerent diseases or condions directly on human paents, in the context of be-
lief systems rooted in parcular cultural tradions. Our modern medical knowledge 
has arisen in the last 200 years as the collecve output of countless physicians, scien-
sts and researchers. Disease modeling in the modern sense is a relavely recent de-
velopment that has arisen as a consequence of the explosion of biological knowledge 
and technology of the last 60 years, parcularly in the ﬁelds of molecular genecs, 
molecular and cellular biology and physiology. For the beer part of the 20th century, 
the mouse has been the most widely used animal model in biomedical research. The 
advantages of the mouse as a model system compared to other alternaves are 
many. The mouse is phylogenecally closer to humans than, say, Drosophila, C. ele-
gans or Danio rerio; it is small, proliﬁc and relavely cheap and easy to maintain, es-
pecially compared to larger models such as pigs, sheep or primates. Importantly, it 
allows in vivo analysis at the organism level. Since the 1980’s, the development of 
techniques for genec manipulaon of the mouse have made this animal one of the 
best available opons for modeling human genec disease. Gene targeng and trans-
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genic technology have led to the development of many mouse models for a wide range 
of both loss and gain of funcon disorders. 
Studies in vivo allow for experimental approaches in the physiological environment of a 
whole organism: interacng cell types and organ systems can be studied in situ or iso-
lated and evaluated in vitro. Inbred strains provide a constant genec background, re-
ducing environmental noise and enhancing reproducibility across laboratories. This is 
important in polygenic and low penetrance genec diseases, allowing the idenﬁcaon 
of single components of the phenotype (Williams et al. 2004).  
While its advantages are well recognized, the mouse system is not without drawbacks. 
While the mouse is relavely phylogenecally close to humans, there exist species-
speciﬁc diﬀerences at mulple levels which limit the ﬁdelity of the mouse system to 
faithfully reproduce many clinical human phenotypes; furthermore, drugs with signiﬁ-
cant impact on mouse models failing in human clinical trials is relavely common. 
(Wilson 1996; Odom et al. 2007; Perel et al. 2007). The genec strategies and manipu-
laons required to reproduce the disease phenotype may be complex and introduce 
unexpected secondary eﬀects (Liu et al. 1998) thus, somemes, further complex ge-
nec manipulaon is needed (Enquist et al. 2007). 
In humans, cellular in vitro models derived from paent biopsies have the advantage of 
oﬀering convenient access to the basic biochemical environment in which the disease 
takes place but the disadvantage that the context and inﬂuence of the higher levels of 
organizaon are lost. Primary culture cells are used for basic studies, drug screening or 
toxicity tests, but their limited proliferaon potenal and the diﬃculty to obtain biop-
sies of aﬀected ssues limit their use. On the other hand, paent mulpotent stem 
cells have higher proliferaon potenal and can be diﬀerenated to a limited number 
of cell types, but are diﬃcult to procure. 
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In recent years, disease models have been established by deriving hESC from genecal-
ly diagnosed preimplantaonal embryos (Pickering et al. 2005; Mateizel et al. 2006) 
and with the derivaon of induced pluripotent stem cells from paent’s biopsied pri-
mary cells. Given their central characterisc of self-renewal and pluripotency, they 
oﬀer both large amount of biological material and the possibility of diﬀerenaon to 
the disease relevant cell types.  
There is no perfect model; all have their advantages and disadvantages. The main ad-
vantage of animal disease models is that they allow in vivo observaons and hypothesis 
tesng all the way up to the organismal level. The main disadvantage is that by their 
very nature of not being human, species speciﬁc diﬀerences can have a profound eﬀect 
on the phenotype. Eﬀorts have been made in humanizing animal models, being able to 
engra human cells in nude mice to perform in vivo experiments, but sll, the physio-
logical environment is not human and some diﬀerences may persist (Watanabe et al. 
2009). In human pluripotent stem cell based disease models, the main disadvantage is 
that they do not provide the physiological environment of a whole organism and their 
principal advantage is being human. Taking this into account, disease models can be 
complemented: human based cell models can be used for studying the molecular 
mechanisms of the disease and as a high through-put system for drug tesng and de-
velopment; meanwhile, animal models, which resemble the human disease phenotype, 
can be used for studying systemic aspects of the disease as well as pharmacokinecs of 
the drugs previously validated on the human cell-based system. 
This PhD dissertaon describes the development of induced pluripotent stem cell 
based models for two lysosomal storage diseases: Gaucher’s Disease and Tay Sachs 
Disease. 
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II. iPSC 
Embryonic pluripotent stem cells are deﬁned by two characteriscs: self-renewal and 
pluripotency. Self-renewal means that they can divide indeﬁnitely without losing their 
pluripotency, which is the ability to diﬀerenate to all the three germ layers of the de-
veloping embryo (ectoderm, mesoderm and endoderm) in vivo and in vitro. Embryonic 
pluripotent stem cells are derived from the inner cell mass of the blastocyst and are 
considered an in vitro equivalent of the inner cell mass populaon. Pluripotent stem 
cells can also be derived from diﬀerenated cells by reprogramming. 
The 2012 Nobel Prize was awarded to John B. Gurdon and Shinya Yamanaka for their 
work on reprogramming mature cells to a pluripotent state. In 1962 John B Gurdon was 
the ﬁrst scienst to use the technique of somac cell nuclear transfer to successfully 
reprogram a somac cell nucleus by transferring it to an enucleated and unferlized 
recipient egg cell, which led to development of a viable organism. (Gurdon 1962). Cel-
lular reprogramming was later achieved with a number of techniques such as somac 
cell fusion with ESC (Tada et al. 2001; Cowan et al. 2005) or EGC (Tada et al. 1997) or 
even the exposure of a somac cell to ESC extracts (Taranger et al. 2005). In these 
techniques the somac cell or nucleus is exposed to reprogramming factors present on 
the cytoplasm of the pluripotent cells. This led Yamanaka to screen 24 pluripotency-
associated genes in order to idenfy the minimum combinaon of factors required to 
reprogram mouse ﬁbroblasts to the pluripotent state. In 2006 Yamanaka’s group pub-
lished that reprogramming of a somac cell could be achieved by ectopic expression of 
four known factors: Oct4, Sox2, Klf4 and c-Myc (OSKM) (Takahashi et al. 2006). The 
resulng pluripotent cells were called induced pluripotent stem cells (iPSC). This re-
markable result oﬀered new approaches for research and therapeuc applicaons, cir-
cumvenng the ethical and immunological caveats of working with hESC (Fig1).  
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Since the ﬁrst iPSC were derived, a number of reprogramming protocols and systems 
have been devised. Reprogramming to iPSC has been achieved with diﬀerent cell types 
(ﬁbroblasts, keranocytes, lymphocytes, cord blood cells and neuronal progenitors, 
among others) and from diﬀerent species reviewed in (Masip et al. 2010); diﬀerent plu-
ripotency factors combinaons have been used (Yu et al. 2007; Feng et al. 2009; Heng 
et al. 2010) and in some cases, the number of factors used has been decreased 
(Huangfu et al. 2008; Nakagawa et al. 2008; Kim et al. 2009). There is also a wide varie-
ty of methods for delivery of the reprogramming factors summarized in Table 1 
(Gonzalez et al. 2011) 
The mechanism by which the ectopic expression of pluripotency factors in a somac 
cell results in reprogramming to the pluripotent state is an acve area of research. It 
has been proposed that during reprogramming, cells undergo three disnct phases 
(Samavarchi-Tehrani et al. 2010). The ﬁrst one involves the establishment of a pre-
Fig 1. Induced pluripotent stem cells. Modiﬁed from hp://www.rndsystems.com/ 
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pluripotent state through the increase of cell cycle rate and compleon of a mesenchy-
mal to epithelial transion (MET). The second phase is the maturaon phase in which 
some embryonic stem cell factors (Nanog, Sall4, Esrrb, Rex1, Tcl1, Cripto and Nodal) 
start to be expressed. And the third phase in reprogramming is the consolidaon of the 
pluripotent state, in which the endogenous pluripotency network becomes independ-
ent from the ectopic transcripon factor expression by epigenec remodeling of chro-
man. The resulng iPSC have proven to be similar to the ESC derived from the inner 
cell mass of the blastocyst, with similar diﬀerenaon capabilies (Boulng et al. 
2011), gene expression and epigenec paerns (Maherali et al. 2007; Okita et al. 2007; 
Wernig et al. 2007; Mikkelsen et al. 2008; Guenther et al. 2010). 
Integrave methods 
Viral 
Retrovirus 
Lenvirus 
DNA Based 
Linearized DNA 
PiggiBac transposon 
Viral 
Adenovirus 
Sendai virus 
Non integrave methods 
DNA Based 
Episomal 
Minicircles 
RNA Based 
Messenger RNA 
microRNAs 
Others 
Protein 
Small molecules 
Table 1. Diﬀerent methods for reprogramming. Reprogramming factors can be delivered into the cells by integrave or 
non-integrave methods which can use viral vectors or DNA based vectors. Non integrave methods also deliver the 
reprogramming factors as mRNA or proteins. MicroRNAs and small molecules have demonstrated to help in the pro-
cess,  rising the eﬃciency and the speed (reviewed in Gonzalez et al. 2011)  
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As models, IPSC present a number of advantages: 1) they are relavely straigh	orward 
to derive, 2) there is a wide range of cell types as starng populaons which can be 
obtained from paent biopsies or cell repositories, 3) potenally, they can be diﬀeren-
ated into the disease speciﬁc relevant cell type populaons, 4) they oﬀer a virtually 
unlimited source of biological material for study or drug screening , 5) if derived from 
paents bearing genec mutaons, no genec engineering is required to create the 
model and 6) panels of iPSC with diﬀerent genotypes of the same disease can be creat-
ed to study mutaon speciﬁc aspects of the disease. 
 
III. Characteriscs of a modelable disease 
Although any disorder with a genec basis is amenable for iPSC modeling, not all dis-
eases present the same challenges. Monogenic diseases are easier to model because 
usually the genec basis is known and phenotypes may be conﬁrmed clearly by rescue 
with the WT gene. Diseases with high penetrance and a cell autonomous phenotype 
are considered more tractable. Polygenic and complex diseases are more diﬃcult to 
model with iPSC due to their strong environmental component. Similarly, early onset 
diseases are more straigh	orward to model than disorders that take decades to devel-
op. Another important feature to have into account is the cellular types aﬀected by the 
disease and the existence of robust diﬀerenaon protocols to derive them from iPSC. 
Such a protocol must be available or needs to be established. Most diﬀerenaon pro-
tocols usually generate heterogeneous populaons in which the required cell type is 
more or less enriched, so puriﬁcaon schemes may be required.. Ideally, the cell phe-
notype must be strong, easily measured and ideally cell-autonomous, not relying on 
the interacons with other cell types, although in some cases co-culturing the implicat-
ed cell type can be aempted (Dimos et al. 2008).  
  10 
 
Some diseases may impair reprogramming and correcng the genec defect prior the 
generaon of iPSC might be required (Raya et al. 2009). Reprogramming process re-
quires cell division and during the process the epigenec landscape of the cell is re-
modeled, so disorders which aﬀect DNA repair, senescence pathways and cell prolifer-
aon, or that involve epigenec mechanisms, may make the generaon of IPSC diﬃcult 
or impossible. On the other hand, given the epigenec base of the reprogramming pro-
cess, even if an epigenec based disease can be reprogrammed to iPSC, it is possible 
that the disease phenotype cannot be recapitulated (Urbach et al. 2010). 
Finally, another factor to consider is the availability and ﬁdelity of alternave disease 
models, parcularly in mouse. Lack of good models for a disease will add value to an 
iPSC model of the disorder, a situaon encountered in many orphan diseases. This PhD 
dissertaon focuses on the development and characterizaon of iPSC models of Gau-
cher and Tay Sachs diseases, both lysosomal storage disorders that fulﬁll many of the 
previous characteriscs. 
 
IV. Gaucher disease 
Gaucher’s disease (GD) is an autosomal recessive lysosomal storage disorder which 
aﬀects 1 in 40,000-60,000 live births in the general populaon and 1 in 400-600 live 
births in Ashkenazi Jews (Grabowski 1993). GD is caused by mutaons in the GBA1 
gene, which encodes for the acid-β-glucosidase (GBA) enzyme (also known as gluco-
cerebrosidase, ceramide β-glucosidase or glucosilceramidase) that catalyzes gluco-
sylceramide (also known as ceramide β-glucoside or glucocerebroside) into ceramide 
and glucose (Brady et al. 1965). Mutaons in the GBA1 gene can cause decreased en-
zyme stability, retenon and degradaon of the enzyme in the endoplasmic reculum 
and impaired traﬃcking to the lysosome (Jmoudiak et al. 2005; Ron et al. 2005). Gluco-
cerebrosidase dysfuncon leads to the accumulaon of glucosylceramide and glucosyl-
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sphingosine in the lysosome of macrophages, Kupﬀer cells, neurons, osteoclasts, T-cells 
and dendric cells causing a mulsystemic clinical presentaon in paents.   
 
Clinical presentacion 
GD clinical features cannot be predicted from the genotype, which are very variable 
and diﬀer from one paent to another, being the most characterisc the hepatosple-
nomegaly due to the presence of gaucher cells. The paents also present hematopoi-
ec abnormalies, neuropathy, bone and pulmonary manifestaons and dermal prob-
lems. GD has been classiﬁed in three diﬀerent clinical groups aending to the onset 
age of the ﬁrst symptoms and the presence and progression of the neurological dam-
age (Knudson et al. 1962).  
Type I. Non neuronopathic (OMIM #230800). The most important feature for its classi-
ﬁcaon is that there are no neurological symptoms. 90% of the GD diagnosed paents 
belong to this clinical group. Also, it is the less severe clinical presentaon of the dis-
ease. It is a systemic presentaon, with great variability in onset, clinical features and 
its progression. Symptoms can appear at any age, ranging from the newborn to the 
elderly paents, but the most frequent age of onset is adulthood. Symptoms include 
hepatosplenomegaly, skeletal defects, hematopoiec abnormalies and in some pa-
ents, dermal pigmentaon, fague, late puberty, renal, pulmonary and cardiac com-
plicaons. 
Type II. Acute neuronopathic (OMIM #230900). It is the least frequent presentaon of 
the disease (1 in 150,000 live births), but also the most severe. It is characterized by 
the early onset of the symptoms and its quick progression. GD type II paents present 
CNS damage in mulple brain structures with gliosis, microglial proliferaon and neu-
ronal degeneraon. Paents start developing the symptoms before the 6th month of 
age and usually die before the 3th year of age. 
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Type III. Chronic neuronopathic (OMIM #2310000). It is an intermediate phenotype 
between type I and II presenng both systemic and neurological symptoms. The symp-
toms appear during childhood or puberty with idencal visceral aﬀectaon as in the 
type I form and a neurological phenotype with a slower progression and less severe 
presentaon than the type II form. 
 
Diagnosis 
Histologicaly, lipid laden macrophages take on a typical morphology (Gaucher cells) 
and can be detected with PAS staining on biopsies from bone marrow, liver or spleen. 
This procedure was the ﬁrst diagnosc test. Nowadays enzymac diagnosis is less inva-
sive and more speciﬁc, using easy-access primary cells as leukocytes or ﬁbroblasts for 
assaying the decrease on the acvity of the GBA (Beutler et al. 1970a; Beutler et al. 
1970b; Beutler et al. 1971). The test is based on the use of 4-methylumbelliferyl-P-D-
glucopiranoside, a synthec substrate of GBA that generates ﬂuorescent 4-MU (4-
methylumberlliferone), that can be detected on a spectroﬂuorometer or by FACS, an 
alternave which is more sensive than the tradional enzymac assay allowing dis-
cerning between healthy, carriers and paents (Rudensky et al. 2003).  
DNA analysis is used for detecng mutaons on the GBA1 gene and in some cases pre-
dicts the progression of the disease as some genotypes are associated with parcular 
progression rates. This genec test is useful for carrier detecon or in prenatal individ-
uals which are possibly aﬀected and also for performing stascs on the populaon. In 
order to facilitate the diagnosis, some methods, enzymac and genec, have been de-
veloped that use dry blood as starng material (Devost et al. 2000; Chamoles et al. 
2002). 
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Treatment 
There is a supporve care treatment for Gaucher paents directed to alleviate its 
symptoms. It includes spleen surgery for the treatment of the cytopenias, blood trans-
fusion in case of anemia, analgesics and the use of prosthesis and/or drugs that inhibit 
the osteoclasts acon as a treatment for the bone injury (Bembi et al. 1994).  
Systemic aspects of the disease can also be treated by enzyme replacement therapy 
(ERT), substrate reducon therapy (SRT) and pharmacological chaperone therapy (PCT) 
for the stabilizaon of the GBA.  
ERT consists of regular intravenous infusion of the modiﬁed GBA so it can be recog-
nized and incorporated into the macrophages. There are four drugs: alglucerase 
(commercialized as Ceredase®) is of placental origin and semisynthec; imiglucerase 
(commercialized as Cerezyme®) which is a recombinant protein expressed in eukaryoc 
cells; α-velaglucerase (commercialized as VRIPV®) produced in ﬁbrosarcoma cell lines, 
and α-taliglucerase (commercialized as Elelyso®) is produced in plant cells. Unfortu-
nately as the recombinant enzyme cannot cross the blood-brain barrier (BBB), ERT as a 
therapeucal opon is limited to the systemic aspects of the disease and is mainly used 
to treat GD types I and III. This treatment has signiﬁcant clinical impact on paents, 
although not all aspects of the disease respond equally well: for example splenohepa-
tomegaly can be reversed, but bone and lung symptoms are more resistant to treat-
ment (Beutler 2004).  
SRT is based on the reducon of the pathogenic accumulaon of glucosylceramide by 
the inhibion of the glucoceramide synthase by imino sugars as N-
butyldeoxynojirimycin (also known as NB-DNJ, Miglustat or Zavesca®). Another drug 
inhibing the glucosylceramide synthesis is the eliglustat tartrate (Genz-112638) which 
is currently in clinical trial phase II. Despite their small size, imino sugars cannot cross 
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the BBB so SRT is only applicable in type I or III paents which cannot be treated by ERT 
or as a complement to other treatments (Aerts et al. 2006). 
Pharmacological chaperones are non-protein compounds that stabilize misfolded pro-
teins protecng them against degradaon by the proteasome and promong their 
traﬃcking to their correct subcellular compartment. For GD, a number of compounds 
have been or are in development, such as imino sugars-based scaﬀolds as N-(n-nonyl) 
deoxynojirimycin (NN-DNJ), the SRT compound NB-DNJ or Isofagomine (IFG) and its 
derivaves. Aminnocyclitols, another type of glycomimec structure diﬀerent from the 
imino sugars have also been studied for their chaperoning capabilies. The small size of 
the chaperone compounds could help in the BBB crossing, but only a few have been 
reported to reach the brain reviewed by (Benito et al. 2011). 
A further opon for treatment of the systemic presentaon (mostly due to  the pres-
ence of Gaucher cells) is  bone marrow transplant, but the associated risks are high and 
ﬁnding a compable donor is diﬃcult (Ringden et al. 1995). 
A related opon is gene therapy by replacement of the mutated GBA1 gene in hemato-
poiec stem cells and is designed to permanently correct the defect. It implies the ex-
tracon of hematopoiec stem cells from the paent and its ex-vivo manipulaon to 
introduce the corrected gene. DNA delivery in these cells is done by lenvirus (Enquist 
et al. 2006; Enquist et al. 2009). Also it has been achieved the expression of GBA in a 
mouse model by adenoviral delivery (McEachern et al. 2006) which can cause random 
inserons in the genome or problems in the autoimmune response. 
Currently, the acute neuronal degeneraon typical of GD type II has no treatment, alt-
hough pharmacological chaperones oﬀer hope in the development of therapies for GD 
able to cross the BBB. 
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Biochemistry 
The GBA enzyme is a lysosomic glycoprotein composed by 497 aminoacids whose mo-
lecular weight depends on its glycosylaon state. The funcon of the GBA is the cataly-
sis of the glucosylceramide into ceramide 
and glucose in the lysosome (Fig 2). GBA 
recognizes glucosylesphingosine as a mi-
nor substrate resulng also in elevated 
levels of this molecule in GD paents 
brain (Nilsson et al. 1982) and plasma 
(Dekker et al. 2011). GBA can also recog-
nize and catalyze arﬁcial β-glucosydic 
substrates, which is useful in the acvity 
tests. 
Glucosylceramide arrives to the lysosome 
by endocytosis (Furst et al. 1992; Sandhoﬀ 
et al. 1994). In an acidic pH, saposin C (SAP C), an acvator of the reacon, is hydropho-
bic, increasing its aﬃnity to the membrane. SAP C joins and aracts GBA. SAP C interac-
on with the membrane destabilizes it, promong the associaon of the GBA to the 
glucosylceramide, favoring the hydrolyzaon of the substrate by GBA.  
 
Genecs 
Gaucher disease heredity is autosomal and recessive. It is caused by mutaons in the 
GBA1 gene and, in a few cases, by mutaons on the gene codifying the prosaposin 
(which will give rise to SAP A, B, C and D). 
Fig2. GBA acvity. Modiﬁed from Sidransky 2004 
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GBA1 gene is located at Chr1q21 (Barneveld et al. 1983; Ginns et al. 1985). At 16Kb 
from the 3’ end of the GBA1 gene there is a pseudogene (Zimran et al. 1990) with a 
high nucleode identy (Horowitz et al. 1989) which may complicate the idenﬁcaon 
of the mutaons. Recombinaon between gene and pseudogene can occur, producing 
non-funconal recombinant alleles. The pseudogene is not translated due to prema-
ture stop codons (Sorge et al. 1990). The GBA1 gene is 10,4Kb long and has 11 exons 
and its cDNA is of 2.5Kb. There are two funconal start codons, separated by 20 amino-
acids which are part of the signal pepde. 
More than 200 mutaons has been described on the GBA1 gene which include mis-
sense mutaons (the majority), inseron or deleon mutaons (some of which result 
in frame shis), non-sense mutaons, splice site mutaons, recombinaon events be-
tween the gene and pseudogene and regulatory mutaons. The most prevalent muta-
ons are p.N370S, p.L444P, 84GG, p.D409H, IVS2+1g>a,  and p.R463C which collecve-
ly account for the 90% and 75% of the total observed GD mutaons in Jews and non-
Jew populaons respecvely (Beutler et al. 1993; Horowitz et al. 1993). 
In general there is a poor genotype-phenotype correlaon in GD. Some relaons have 
been established, but even in homozygotes the phenotype may vary between individu-
als.  The presence of the mutaon p.N370S in at least one of the alleles ensures a type I 
phenotype with no neurological aﬀectaon, with the second allele inﬂuencing the se-
verity of the overall phenotype (Zimran et al. 1989; Cormand et al. 1997). On the other 
hand, the presence of the mutaon p.L444P is associated to neuronopathic forms of 
the disease (type II and III) (Koprivica et al. 2000; Stone et al. 2000). In homozygosis, 
p.L444P usually leads to type III form and if associated with a null mutaon in heterozy-
gosis, the phenotype will be type II. Homozygote p.D409H paents present a rare form 
of the type III characterized by cardiac complicaons (Abrahamov et al. 1995; Chabas 
et al. 1995). The presence of Rec alleles (recombinaon between the GBA and the GBA 
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pseudogene) in homozygosis leads to the perinatal lethal form of the disease (Tayebi et 
al. 2003).  
 
Models 
Modeling Gaucher Disease in the mouse has been surprisingly diﬃcult and most in 
vitro studies for the study of the mechanism of the disease and drug tesng have been 
done in paent ﬁbroblasts. 
The analysis and characterizaon of diﬀerent mutants of the GBA1 gene has been pos-
sible by using diﬀerent expression systems as baculovirus and Spodoptera frugiperda 
(army worm) (Grabowski et al. 1989; Grace et al. 1990; Choy et al. 1996; Grace et al. 
1999) or vaccinia expression system infecng BSC40 or HeLa cells (Hodanova et al. 
2003), or by transfecon in NIH3T3 (Ohashi et al. 1991) or COS cells (Grabowski et al. 
1989; Alfonso et al. 2004). These systems were used to study the catalyc acvity of 
the enzyme and its possible correlaon with the genotype. 
Expressing the GBA can give a lot of informaon of the enzyme, its acvity and kinecs, 
but the used models can contribute lile to the knowledge of the phenotype produced 
in the diﬀerent cells and less to the disease phenotype observed in the paents. Sever-
al aempts have been done trying to model GD in mouse. The ﬁrst one was a KO of the 
GBA1 gene, newborns had a GBA acvity of 4% and died at 24 hours aer birth 
(Tybulewicz et al. 1992).  
Mice models resembling the human point mutaons on the GBA1 gene appeared later 
creang by site-directed mutagenesis RecNciI and p.L444P which both correlate with 
types II and III forms of GD respecvely. RecNciI homozygous mice presented low GBA 
acvity and accumulaon of glucosylceramide in brain and liver; meanwhile, p.L444P 
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homozygous mice had higher GBA acvity than RecNcil and showed no detectable ac-
cumulaon of glucosylceramide in neither brain nor liver. Both homozygous mutants 
died at 48 hours aer birth due to problems in the epidermal permeability barrier 
caused by the lack of glucosylceramide in the epidermis (Liu et al. 1998). A p.L444P ho-
mozygous mouse model was possible when combined with a heterozygous KO of the 
glucosylceramide synthase. These mice were able to live more than a year showing a 
mulsystemic inﬂammaon; but no Gaucher cells were found nor a large accumulaon 
of glucosylceramide (Mizukami et al. 2002). Mouse models for the point mutaons 
p.N370S, p.V394L, p.D409H and p.D409V have also been developed. Human paents 
with p.N370S homozygosis present the type I form of the disease, the mildest form; in 
contrast, p.N370S homozygous was lethal in the newborn mice. The other mutants pre-
sent a reduced GBA acvity and a glucosylceramide accumulaon in visceral organs but 
never in the brain (Xu et al. 2003). 
The only murine models which show neuronopathic features as rapid motor neuron 
dysfuncon, seizures, neurodegeneraon and apoptoc neuronal cell death, are the 
developed by Enquist and colleagues (Enquist et al. 2007) which had low GBA expres-
sion in the skin in order to prevent the early lethality observed in other Gaucher dis-
ease GBA KO models. Using these models it was determined that microglial cells are 
not the primary cause, but inﬂuence in the progression of the neurological eﬀects.  
Although valuable for the study of the loss of funcon of GBA, the model developed by 
Enquist is not a reproducon of the mutants observed in the human populaon, so, 
even if some of the features of the disease are recapitulated and we can increase our 
knowledge on the metabolism of the diﬀerent ssues in the disease, we cannot use 
Enquist model for drug tesng because the system lacks the expression of the deﬁcient 
GBA.  
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Gaucher disease features have been reproduced in iPSC derived from paent ﬁbro-
blasts type I (p.N370S/ p.N370S), type II (p.L444P/RecNcil and p.L444P/p.G202R) and 
type III (L444P/L444P) (Park et al. 2008; Panicker et al. 2012; Tiscornia et al. 2013). 
Diﬀerenaon of the obtained iPSC into macrophages and neurons recapitulated the 
phenotypic hallmarks of the disease and demonstrated to be a good pla	orm for drug 
screening. 
 
V. Tay Sachs disease 
Tay Sachs disease is an autosomal recessive lysosomal storage disorder included in the 
group of GM2 gangliosidoses which aﬀects 1 in 360.000 newborns in the general popu-
laon and 1 in 2500-3600 in Ashkenazi Jews. TS is caused by mutaons on the HEXA 
gene, which encodes for the α-subunit of the β-hexosaminidase A enzyme (HexA) that 
is part of the complex that catalyzes ganglioside GM2 degradaon. This leads to GM2 
ganglioside accumulaon on the lysosomes of neuronal cells, interfering with the nor-
mal cell acvity and causing neuronal degeneraon. 
 
Clinical presentaon 
Several diﬀerent variants of the Hex α-subunit deﬁciency have been found, correlang 
the enzymac residual acvity to the clinical phenotype: the higher the acvity of the 
HexA, the later and milder the symptoms. Tay Sachs has three diﬀerent clinical mani-
festaons: infanle acute and two late onset forms subacute and chronic. Late onset 
forms cover manifestaons from late infanle period to adult age. (Gravel et al. 2001) 
In the infanle acute form the ﬁrst symptoms appear at age 3-5 months with weak-
ness, hampered growth, lack to response to external smuli and loss of mental and 
motor skills. Observaon with an ophthalmoscope reveals the classical cherry red spot 
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(Fig 3). Paents suﬀer of progressive weakness and hypoto-
nia. Seizures start some months aer the neurological man-
ifestaons and increase with the progression of the disease. 
Also progressive blindness and marked hyperacusis appear 
before the year. Aer 10 months of age, there is a rapid 
progression of the disease, increasing the severity of the 
symptoms; by the 18th month macrocephaly can be ob-
served. On the last stage of the disease, the children show decerebrate body posturing, 
diﬃcules for swallowing and are completely unresponsive to external smuli. Death 
usually occurs between age 2 and 4.  
Late onset subacute form: it starts with ataxia at age between 2 and 10 years. There is 
a progressive psychomotor deterioraon and dystonia in parallel to developmental 
regression and demena, involving speech impairment. Blindness occurs later than in 
the acute infanle as well as seizures. By the age of 10 to 15 years, paents are in a 
vegetave state and die few years later. 
Late onset chronic: can appear at any point from childhood to adulthood, presenng 
great variability in the clinical manifestaons and progression. Symptoms include psy-
chomotor deterioraon, dystonia, spinocerebellar degeneraon, dysarthria and psy-
choc manifestaons. 
 
Diagnosis 
Enzymac acvity assays are common for TS diagnoses and can be performed from 
serum, leukocytes (Suzuki et al. 1971), ﬁbroblasts (Okada et al. 1971) and even dried 
blood samples (Lukacs et al. 2011). Detecon of α subunit deﬁciency in HexA enzyme is 
achieved by synthec chromogenic or ﬂuorogenic substrates as 4-methylumbelliferyl-2
Fig 3. Cherry red spot observed in 
the infanle acute form of Tay 
Sachs disease 
  21 
 
Introducon 
-acetamido-2-deoxy-β-D-glucopyranoside (MUG) and 4-methylumbelliferyl-2-
acetamido-2-deoxy-6-sulfo-β-D-glucopyranoside (MUGS) which, upon hydrolysis, 4-
methylumbelliferone is released and can be detected ﬂuorometrically. HexA isoenzyme 
(αβ) can degrade both substrates meanwhile HexB (ββ) can only degrade MUG. For TS 
paent diagnosis enzymac analysis of HexA acvity (MUGS degradaon) is expressed 
as a percentage of total Hex acvity (MUG) (Hechtman et al. 1993). Also, diﬀerenal 
heat stability of HexA respect HexB is used for paent diagnosis by measuring acvity 
before and aer inacvang HexA by heat; HexA acvity is the diﬀerence between the 
two measured acvies (Kaback et al. 1977). Prenatal diagnoses can be performed 
with amnioc ﬂuid or chorionic villus samples (Grabowski et al. 1984; Callahan et al. 
1990). 
When enzymac assays show HexA deﬁciency, DNA analysis is essenal to conﬁrm the 
phenotype and evaluate the possible progression of the disease regarding the geno-
type. DNA analysis is also useful for populaon screening as the carried out on Jewish 
in order to idenfy carriers and couples at risk of breeding aﬀected children and re-
ceive proper genec counseling 
 
Treatment 
Sadly, there is no treatment for Tay Sachs in which the progression of the disease is 
reversed not even halted. The therapy for these paents is focused on supporve care. 
Nevertheless diﬀerent therapeuc approaches are being studied as enzyme replace-
ment therapy (ERT), substrate reducon therapy (SRT), bone marrow transplantaon, 
gene therapy, or the last one, the inducon of exocytosis.  
ERT in TS has been tried in humans with no success (Johnson et al. 1973; von Specht et 
al. 1979). TS pathophysiology is centralized in the nervous system which means that 
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the treatment enzyme must overcome two barriers to succeed. One is crossing the 
blood brain barrier, which was assessed by intrathecal inﬁltraon of the enzyme with 
no successful results (von Specht et al. 1979). The other is eﬃciently targeng to the 
neurons for which mannose-6-phosphate must be on the surface of the enzyme for 
neuronal recognion and uptake. In this sense, recombinant phosphomannosylated 
HexA enzymes are being produced and inial results in mice and human ﬁbroblast are 
promising (Akeboshi et al. 2007; Akeboshi et al. 2009; Tsuji et al. 2011). 
SRT have been focused on the inhibion of glucosylceramide synthase by N-
butyldeoxynojirimycin (NB-DNJ) also known by miglustat. Studies of miglustat admin-
istraon to TS and Sandhoﬀ model mice show a diminuon of GM2 accumulaon in the 
brain and in the severity of the neuropathology (Pla et al. 1997; Baek et al. 2008). 
Nevertheless, when these studies were carried with human paents no improvement 
of the symptoms was observed (Maegawa et al. 2009; Shapiro et al. 2009) maybe be-
cause in mice, the HEXA gene deﬁciency does not produce such an accumulaon of GM2 
as it does in humans. 
Cell therapy has been tried by bone marrow transplant with no beneﬁt for the paent 
(Hoogerbrugge et al. 1995). Also, correcon of the enzymac defect has been tried by 
viral delivery on neural progenitors which then were implanted on the mice brain or 
introduced directly into the brain (Lacorazza et al. 1996; Marno et al. 2005; Cachon-
Gonzalez et al. 2006) with promising results but sll need to be probed their eﬃcacy in 
human paents. 
Pharmacological chaperone pyrimethamine was found by screening of already ap-
proved compounds of the Food and Drug Administraon (Tropak et al. 2007) and has 
already been tested in TS paents with an increase on HexA acvity, but sll with no 
clear signs of neurological improvement due to the short term study (Clarke et al. 
2011; Osher et al. 2011). Other pharmacological chaperones are being designed and 
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tested in TS cell lines (Rountree et al. 2009) but further studies are needed to test their 
eﬃciency in paents. 
A new drug target for treang lysosomal storage diseases is the lysosomal exocytosis. 
Promong lysosomal exocytosis by increasing intracellular Ca2+ levels can restore nor-
mal lysosome size and content in lysosomal storage diseases, including TS (Klein et al. 
2005; Medina et al. 2011; Xu et al. 2012). 
 
Biochemistry  
Gangliosides are glicosphingolipids formed by a ceramide (N-acylsphingosine) and an 
oligosaccharide chain which contains one or more molecules of sialic acid (N-
acetylneuraminic acid, NANA or NeuAc) (Berg et al. 2007). They localize on the plasma 
membrane with the oligosaccharide chains on the extracellular matrix (Thompson et al. 
1985). The highest ganglioside concentraon is found on the gray maer of the brain 
(Ando 1983), parcularly in the plasma membranes of nerve endings, dendrites and 
synapses (Hansson et al. 1977). Gangliosides are involved in cell-cell interacon, patho-
gen binding, co-receptors in hormone signaling and it has been hypothesize their im-
portance in the synapse and neu-
ronal transmission (Rahmann et al. 
1976; Ando 1983).  
Ganglioside biosynthesis starts from 
ceramide at the cytosolic leaﬂet of 
the ER, going through Golgi where 
glycosyltransferases and sialyltrans-
ferases add in sequence the corre-
sponding carbohydrate component. 
Fig 4. GM2 ganglioside structure 
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Gangliosides reach the plasma membrane by vesicle ﬂow. GM2 ganglioside is formed by 
a lactosylceramide with a NeuAc and an N-acetylgalactosamine residue (Fig 4). For GM2 
degradaon, plasma membrane is endocytosed passing through endosomal compart-
ments to reach the lysosome. There, HexA enzyme starts GM2 degradaon with the help 
of the GM2 acvator which lis and exposes the carbohydrate chain to the HexA en-
zyme, allowing the excision of the terminal N-acetylgalactosamine residue (Gravel et al. 
2001). 
HexA enzyme is composed by two subunits: an α-subunit of approximately 55KDa and 
a β-subunit of about 23KDa. Subunit α is encoded by HEXA and subunit β is encoded by 
HEXB gene. There are two other hexosaminidases isozymes, HexB which is composed 
by two β subunits (ββ) and HexS, composed by two α subunits (αα), but only HexA can 
degrade GM2. GM2 gangliosidoses are caused by mutaons in any of the the HexA subu-
nits α (Tay Sachs), β (Sandhoﬀ) or in the GM2 acvator (AB variant). 
 
Genecs 
Tay Sachs disease is caused by mutaons on the HEXA gene which encodes for the α-
subunit of the HexA enzyme. HEXA gene is located in Chr15q23 and contains 14 exons, 
expanding 35kb length (Proia et al. 1987; Takeda et al. 1990).  
More than 100 mutaons have been found on HEXA gene (Kaback 2000) including 
large and small deleons, missense, nonsense, frame-shi and splice site alteraons. 
The clinical presentaon is closely related to the residual acvity of the HexA enzyme. 
Mutaons on the HEXA gene causing a full deﬁciency of the α-subunit are associated 
with the infanle acute form of the disease. This include small in-dels causing frame-
shi and the majority of splicing mutaons as the cases of the two most common mu-
taons  in infanle TS among Ashkenazi Jews, the 1278ins4 (Myerowitz et al. 1988) and 
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the IVS12+1 G>C (Arpaia et al. 1988; Myerowitz 1988; Ohno et al. 1988). Other muta-
ons related to the infanle form are those aﬀecng protein processing as E482K, 
R504C and G269S (d'Azzo et al. 1984; Nakano et al. 1988; Paw et al. 1991) 
Late onset subacute form is associated with mutaons that maintain some residual 
acvity of the HexA and include aminoacid substuons as G250D (Trop et al. 1992) 
and two mutaons aﬀecng α-subunit processing R499H and R504H (Paw et al. 1990), 
in which the hisdine allows some phosphorylaon so the α-subunit can associate with 
the β and become into HexA acve enzyme on the lysosome. Late onset subacute is 
also related to B1 variant mutaons in which the mutaons do not alter the associaon 
of α and β subunits, but alters the acvity of the HexA as are the mutaons observed in 
R178 and D258 (Tanaka et al. 1990; Triggs-Raine et al. 1991; Fernandes et al. 1992).  
In the case of the late onset chronic form, there is one major mutaon associated 
which is G269S (Paw et al. 1989) which is common between Ashkenazi Jews.  
 
Models 
GM2 gangliosidoses are naturally occurring in animals as dogs, cats, pigs, sheep and 
even ﬂamingos (Pierce et al. 1976; Neuwelt et al. 1985; Zeng et al. 2008; Torres et al. 
2010; Sanders et al. 2013), but usually are sporadic excepons, studies post-mortem 
and are not maintained as a lineage.  
Diﬀerent Tay Sachs murine models have been developed by interrupon of exon 8 or 
exon 11 of the HEXA gene (Yamanaka et al. 1994; Boles et al. 1995; Cohen-Tannoudji et 
al. 1995; Phaneuf et al. 1996). Biochemically, HexA is inacve, but Tay Sachs mice do 
not develop the clinical features observed in human. Unlike humans, mice can degrade 
GM2 by HexA acvity or by sialidase acon, performing a bad model for studying TS mu-
taons and tesng drugs. For the study of the eﬀect of GM2 accumulaon it is used the 
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Sandhoﬀ mice model, which lacks HexB acvity and recapitulates hallmarks of the hu-
man GM2 gangliosidosis.  
Recently, it has been proved that cultures of NPC can mimic the hallmarks of the brain 
disease, but again, the NPC used were derived from mice and are useless for biochemi-
cal studies on HexA funcon or drug discovery (Marno et al. 2009). 
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Objecves 
 
In the context of the CMRB, whose principal aim is to apply the knowledge on stem 
cell to the study of diseases and the seek of possible cellular therapies; the main 
objecve of the thesis was to apply the technology of iPSC to genec diseases for 
modeling.  
 
The speciﬁc objecves of the study are: 
1. Generaon and characterizaon of iPSC lines from Gaucher and Tay 
Sachs paent ﬁbroblasts.  
2. Diﬀerenaon of the cell lines into appropriate ssues and corrobora-
on of the disease phenotype. 
3. Use of the developed models in drug tesng and conﬁrm phenotype 
reversion. 
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Cell Culture 
All the cell lines were cultured at 37oC, 5% CO2, 90% humidity 
HFF culture and irradiaon 
HFF-1 cell line was fed with IMDM media and media was changed every 2-3 days. 
When the culture reached 80-90% of conﬂuence, cells were passaged by trypsiniza-
on with trypsin-EDTA 0,25% (Invitrogen #25300-056) and seeded at a density of 
70.000 cells/cm2. 
For irradiaon, cells were grown unl 100% of conﬂuence, trypsinized, resuspended 
in IMDM media and irradiated at 45Gy. IrHFF were frozen in freezing media (4x106 
irHFF per vial). IrHFF were plated on gelan-coated plates at a density of 3x106 irHFF 
in a 10cm plate if freshly irradiated or at a density of 4x106 irHFF in 10cm plate if 
thawed from a frozen vial. 
MEF isolaon and irradiaon 
MEFs were derived from E13,5-E14,5 day old CD1 strain embryos. The liver was ex-
cised from the embryos which were then decapitated and bled. Embryos were 
minced and trypsinizated with trypsin-EDTA 0.05% (Invitrogen #25300-054) for 20-30 
minutes and ﬁltered through a 40μm cell strainer. Resulng cells were seed in a rao 
of 2 embryos per 15cm plate and fed with DMEM complete media containing 2% P/S 
(Gibco #15140-122). Upon reaching 100% of conﬂuence, MEFs were passaged with 
trypsin-EDTA 0,05% in a rao 1:3-1:5. 
For irradiaon MEFs were ampliﬁed 1:6 up to passage 4. When ﬁbroblasts reach 
100% conﬂuence they are treated with 0,25% trypsin-EDTA, resuspended in DMEM 
complete medium and irradiated at 45Gy. IrMEFs were frozen in freezing media 
(4x106 irMEFs per vial). IrMEFs were plated on gelan (Chemicon #ES-006-B) coated 
plates at a density of 3x106 irMEF in a 10cm plate if freshly irradiated or at a density 
of 4x106 irMEF in 10cm plate if thawed from a frozen vial. 
PA6 culture 
The mouse bone marrow–derived stromal cell line PA6 was maintained in PA6 media 
and passed by trypsinizaon with 0,05% trypsin-EDTA in a rao 1:3-1:6 
OP9 culture 
The murine stromal cell line OP9 was maintained in OP9 media. When cells achieved 
85-95% of conﬂuence they were passaged 1:3 by trypsinizaon with 0,05% trypsin-
EDTA. 
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Obtenon and culture of GD and TS paent ﬁbroblast 
Gaucher disease ﬁbroblasts were obtained from a paent diagnosed with GD type2 
following the protocol approved by the Hospital Clinic de Barcelona. Brieﬂy, the biopsy 
sample was cut and seed in a dish with DMEM complete media. When ﬁbroblasts were 
conﬂuent, cells were passaged with 0,05% trypsin-EDTA. Paent diagnosis was based 
on the clinical manifestaons and a low acid-β-glucosidase acvity. Analysis of the 
GBA1 gene sequence conﬁrmed the presence of a p.[Leu444Pro];[Gly202Arg] com-
pound heterozygote mutaon. 
Tay Sachs ﬁbroblasts were obtained from the Coriell Cell Repository sample #GM00527 
which contain a compound heterozygote mutaon of p.[Trp420Cys](c.1260G>C) in one 
allele and IVS11+1G>A (c.1330+1G>A) in the other. 
GD ﬁbroblasts, TS ﬁbroblasts and WT ﬁbroblasts were cultured in DMEM complete me-
dia. 
iPSC derivaon 
2μg of the reprogramming DNA were nucleofected into 106 low passage GD and TS ﬁ-
broblasts with the NHDF nucleofecon kit (Lonza #VPD-1001) following the manufac-
turer’s protocol. The nucleofected ﬁbroblasts were seed on irradiated HFF feeder layer, 
and fed every other day with HES media for one week, aer which  HES was replaced 
by HES condioned media. Aer 4-6 weeks colonies appeared on the plate and were 
picked manually for expansion. 
iPSC culture 
GD, TS and WT iPSC were cultured on irHFF feeder layers and fed with HES media. Cells 
were passaged mechanically every 7-10 days. In order to obtain pure iPSC without 
feeder contaminaon, iPSC were seed on matrigel (Becton Dickinson #356231) coated 
plates with 6x105 irHFF and fed with HES condioned media. Aer 1-2 passages, iPSC 
were seed on matrigel coated plates, fed with HES condioned media and passaged by 
trypsinizaon with Trypsin-EDTA 0.05%. 
Reprogramming cassee eliminaon 
iPSC lines cultured on matrigel were treated for 1 hour with a Rock inhibitor (Y27632) 
then were trypsinized and transduced in suspension with a non-integrave lenviral 
vector expressing Cre recombinase and cherry ﬂuorescent protein. They were plated 
on irHFF feeder layer and fed with HES condioned media. 72 hours later cherry posi-
ve cells were sorted by FACS and plated for subclone isolaon. Loss of the reprogram-
ming cassee was conﬁrmed by southern blot. 
GBA1 and HexA rescue 
GD and TS iPSC lines were genecally rescued by transducon with a lenviral vector 
constuvely expressing GBA1 or HexA, respecvely. iPSC lines cultured on matrigel 
were treated for 1 hour with a Rock inhibitor (Y27632) then were trypsinized and trans-
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duced at low mulplicity of infecon. Subclones were screened for lenviral integra-
on by PCR, followed by an acid-β-glucosidase acvity assay. 
iPSC characterizaon 
IPSC lines were tested for alkaline phosphatase acvity using the Blue Membrane Sub-
strate soluon kit (Sigma #AB0300) following the manufacturer’s guidelines. 
Pluripotency was tested on iPSC colonies growing on irHFF covered slide ﬂasks by im-
munoﬂuorescence with anbodies against Oct4 (Santa Cruz #sc-5279), Sox2 (ABR #PAI-
16968), Nanog (R&D #AF1997), Tra1-60 (Chemicon #MAB4360), Tra1-81 (Chemicon 
#MAB4381), SSEA3 (Hybridoma Bank #MC-631) and SSEA4 (Hybridoma Bank #MC-813-
70) pluripotency markers (Mar et al. 2013). 
iPSC in vitro diﬀerenaon into endoderm 
iPSC were detached and cultured as EBs on ultra-low aachment cell culture plates in 
EB media for 3 days in suspension. 6-10 EBs were plated per slide ﬂask (pre-coated 
with gelan 0.1%) and fed with EB media each 2-3 days unl 15-20 days. Samples were 
then ﬁxed with PFA 4% (Sigma #P6148-500G) and immunostained for endodermal 
markers as AFP (Dako #A0008) and FoxA2 (R&D #AF2400). 
iPSC in vitro diﬀerenaon into mesoderm 
iPSC were detached and cultured as EBs on ultra-low aachment cell culture plates in 
EB media supplemented with 0.5mM ascorbic acid (Sigma #A4544-25g) for 3 days in 
suspension. 6-10 EBs were plated per slide ﬂask (pre-coated with gelan 0.1%) and fed 
with EB media supplemented with 0.5mM ascorbic acid each 2-3 days unl 15-20 days. 
Then, samples were ﬁxed with PFA 4% and immunostained against mesodermal mark-
ers as ASMA (Sigma #A5228) and ASA (Sigma #A2172). 
iPSC in vitro diﬀerenaon into ectoderm 
iPSC were detached and cultured as EBs on ultra-low aachment cell culture plates in 
N2/B27 media for 4 days in suspension. 6-10 EBs were plated on a conﬂuent PA6 cells 
slide ﬂasks pre-coated with gelan 0.1% and fed with N2/B27 media each 2-3 days unl 
14-16 days.  Samples were then ﬁxed with PFA 4% and immunostained against ectoder-
mal markers Tuj1 (Covance #MMS-435P) and GFAP (Dako #Z0334). 
iPSC in vivo diﬀerenaon 
106 iPSC were injected into the tess of SCID beige mice and 8–12 weeks later terato-
mas were surgically removed, ﬁxed in PFA 4% and immunostained against endoderm 
(AFP and Foxa2), ectoderm (Tuj1, GFAP) and mesoderm markers (ASMA and ASA). All 
animal experiments were conducted following experimental protocols previously ap-
proved by the Instuonal Ethics Commiee on Experimental Animals, in full compli-
ance with Spanish and European laws and regulaons 
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Lenviral producon 
A third generaon lenviral system was used following previously published protocols 
(Tiscornia et al. 2006). 1,2x107 of 293T cells were plated in a 150mm plate coated with 
poly-L-Lysine in DMEM complete media. 24 hours later DNA (HIV based vector plasmid, 
pMDL, pRev and pVSV-G) transfecon was performed with PEI (Polysciences #24765) in 
a 4:1 rao (PEI:DNA). Aer 16 hours media was changed for 15ml of OpMEM (Gibco 
#11058-021) per 150mm plate. Media with the viral parcles was collected at 24 and 
48 hours aer OpMEM was added for the ﬁrst me, ﬁltered through a 0.22μm ﬁlter 
and ultracentrifuged at 19.4k rpm (Beckman Coulter OpmaTM L-90k Ultracentrifuge 
SW32 rotor) for 2hours and 20minutes. Pellet was resuspended in PBS (Cambrex #17-
516F), aliquoted and stored at -80oC. 
Diﬀerenaon to dopaminergic neurons 
iPSC were diﬀerenated to dopaminergic neurons using previously published protocols 
(Cho et al. 2008a; Cho et al. 2008b). 
Step 1: iPSC were detached and cultured as EBs on ultra-low aachment cell culture 
plates in Cho EB media for 5-7 days changing media every other day. EBs were trans-
ferred to matrigel coated plates and maintained with NPSM for 5 days with media 
change every other day and cysts were removed. Aer 5 days on NPSM, media was 
changed to NPEM with media change every other day for 7 days more.  
Step 2: neural structures were mechanically dissected and cultured on suspension on 
ultra-low aachment plates and were fed with NPEM every other day. Neural struc-
tures formed SNMs which were cultured with NPEM with media change every other 
day and mechanically passaged every 10 days.  
Step 3: SNMs were dissected in very small pieces (1 SNM  ̴  10-20pieces) and seed on 
matrigel coated slide ﬂasks with NPEM. Aer 24 hours, NPEM was replaced by NDM 
(day 1 of diﬀerenaon). On day 4 NDM was supplemented with 200ng/ml SHH 
(Peprotech #100-45) and 100ng/ml FGF8 (Peprotech #100-25). On day 8, ascorbic acid 
(Sigma #A4544-25g) at a ﬁnal concentraon of 200μM was added to the NDM supple-
mented with SHH and FGF8 and media was changed every other day unl the end of 
the protocol (day 14 of diﬀerenaon). 
Chaperone treatment 
Chemical chaperones were synthesized and characterized by C. Orz Mellet and JM 
García Fernández as described (Luan et al. 2009; Aguilar-Moncayo et al. 2011). Fibro-
blasts were treated with chaperone compounds at 30μM ﬁnal concentraon for 4 days 
maintaining their culture condions. The treatment in neurons was performed in the 
last 4 days of the dopaminergic diﬀerenaon, adding the chemical chaperones at 
30μM ﬁnal concentraon to the supplemented NDM. 
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Organic compounds treatment 
Organic compounds NCGC00160622-03 and NCGC00250218-01 were synthesized and 
characterized by Juan Marugán’s group. Fibroblasts were treated with organic com-
pounds at diﬀerent concentraons for 5 days maintaining their culture condions. The 
treatment in neurons was performed in the last 5 days of the dopaminergic diﬀerena-
on, adding diﬀerent concentraons to the supplemented NDM. 
iPSC diﬀerenaon to macrophages 
Step 1 (Raya et al. 2009): iPSC were detached and cultured as EBs on ultra-low aach-
ment cell culture plates in HES media supplemented with 100 ng/ml mWNT3a 
(Peprotech #315-20) for 2 days. Then EBs were transferred onto OP9 feeders in a 1:1 
mix of HES media and hematopoiec diﬀerenaon media. Aer 2 days media was 
changed to hematopoiec diﬀerenaon media. The following media change was per-
formed by replacing of half volume of media for fresh media in 3-4 days. Further media 
changes were performed each 3-4 days by replacing 25% of media with fresh media for 
a total of 14 – 16 days. 
Step 2 (Choi et al. 2011): cultures were trypsinized with 0.25% trypsin-EDTA, 0.1% col-
lagenase type IV and DNAse I, washed with PBS and cultured in ultra-low aachment 
dishes in Macrophage diﬀerenaon media A for 2 days. Then cells were washed with 
PBS and cultured in Macrophage diﬀerenaon media B for addional 10 days. At this 
me, cells were collected, ﬁltered through 100 μm cell strainer and used for further 
experiments. 
Phagocytosis assay 
For live cell imaging of phagocytosis, 50.000 cells were plated onto glass boom dishes 
in 400μl of Macrophage diﬀerenaon media B and were allowed to aach overnight. 
Next day, media was replaced with 200μl of fresh Macrophage diﬀerenaon media B 
supplemented with opsonized FITC-Zymosan A parcles (Life Technologies #Z2841) at a 
rao of 20 parcles per cell. Aer 100 minutes, non-internalized parcles were washed 
away with PBS; cells were stained with Hoechst vital dye and analyzed with a confocal 
Leica SP5 AOBS microscope. For FACS analysis of phagocyc macrophages, cells were 
cultured in 12-well cell culture dishes at a density of 200.000 – 500.000 per well, treat-
ed with opsonized FITC-labeled Zymosan A parcles, trypsinized and in some experi-
ments stained with an-CD14 anbody. 
Media formulaon 
DMEM complete DMEM (Gibco  #21969-035), 10% FBS (Gibco #10270-106), 1% Gluta-
MAX (Gibco #35050-038), 1% P/S (Gibco #15140-122) 
IMDM media IMDM (Gibco # 21980-032), 10% FBS, 1% P/S 
Freezing media 90% FBS, 10% DMSO (Sigma #D2650) 
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HES media KO DMEM (Gibco #10829-018), 20% KSR (Gibco #10828-028), 1% MEM NE-
AA (Cambrex #13-114), 1% GlutaMAX, 0.1% β-Mercaptoethanol (Gibco #31350-010), 
0.5% P/S and 10ng/ml bFGF (Peprotech) 
HES condioned media Seed 4x106 irMEFs in a 10cm plate. Aer 24 hours, DMEM com-
plete media was replaced by HES media.  HES condioned media was harvested daily, 
ﬁltered through a 0.22μm ﬁlter and supplemented with 10ng/ml bFGF 
EB media KO DMEM, 10% FBS, 1% P/S, 1% GlutaMAX, 1% MEM NEAA, 0.1% β-
Mercaptoethanol 
PA6 media α-MEM with Ribonucleosides/Deoxyribonucleosides (Gibco #32571), 10%
FBS, 1% P/S, 1% GlutaMAX 
N2/B27 media 50% DMEM/F12 (Gibco #21331-046), 50% Neurobasal media (Gibco 
#21103-049), 1% P/S, 1% GlutaMAX, 0.5% N2 (Invitrogen #17502048), 1% B27 
(Invitrogen #17502044) 
Cho EB media DMEM/F12, 20% KSR, 1% GlutaMAX, 1% MEM NEAA, 1% P/S, 0.2% β-
Mercaptoethanol 
Neural Precursor Selecon Media (NPSM) DMEM/F12, 1% GlutaMAX, 1% MEM NEAA, 
1% P/S, 0.2% β-Mercaptoethanol, 0.5% N2 supplement 
Neural Precursor Expansion Media (NPEM) DMEM/F12, 1% GlutaMAX, 1% MEM NEAA, 
1% P/S, 0.2% β-Mercaptoethanol, 1% N2 supplement, 20ng/ml bFGF 
Neuronal Diﬀerenaon Media (NDM) DMEM/F12, 1% GlutaMAX, 1% MEM NEAA, 1% 
P/S, 0.2% β-Mercaptoethanol, 1% N2 supplement, 2% B27 supplement 
OP9 media α-MEM without Ribonucleosides/Deoxyribonucleosides (Gibco #32561), 
20% FBS, 1% P/S, 1% GlutaMAX 
Hematopoiec diﬀerenaon media IMDM, 10% FBS (Cultek #16SV30160-03), 1% P/S, 
1% GlutaMAX, 10ng/ml bFGF, 10 ng/ml Flt3l (Peprotech #300-19), 10 ng/ml VEGF 
(Peprotech), 10 ng/ml BMP-4 (Peprotech), 20 ng/ml TPO (Peprotech #300-18), 25 ng/
ml SCF (Peprotech  #300-07) 
Macrophage diﬀerenaon media A α-MEM without Ribonucleosides/ Deoxyribonu-
cleosides, 10% FBS (Cultek), 1% P/S, 100μM MTG soluon (Sigma) and 200ng/ml GM-
CSF (Peprotech #300-03) 
Macrophage diﬀerenaon media B IMDM, 10% FBS (Cultek), 1% P/S, 20ng/ml M-CSF 
(Peprotech #300-25) and 10ng/ml Il-1β (Peprotech #200-01B) 
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Imaging 
Karyotyping 
iPSC were treated with colcemid (Invitrogen #15212-046) for 40 minutes (ﬁbroblasts 
for 2 hours). Aer colcemid incubaon, cells were trypsinized in order to obtain a sin-
gle cell diluon and pelleted. Cell pellet was resuspended in 0,075M KCl (Invitrogen 
#10575) and cold Carnoy ﬁxave (methanol and acec acid in a 3:1 rao) was added. 
Cells were resuspended in Carnoy ﬁxave, then were disrupted by falling to a slide 
from a height of 50cm. Samples were dried for 24 hours incubated at 120oC for 1,5 
hours. Samples were stained with Wright dye and analyzed with Leica CytoVision 
pla	orm. 
Pluripotency and diﬀerenaon immuno-analysis 
Slide ﬂasks containing iPSC for analyzing pluripotency or diﬀerenang EBs were ﬁxed 
with 4% PFA for 30 minutes. Samples were incubated in blocking soluon (1x TBS, 0,5% 
Triton, 6% Donkey serum) for 30 minutes and then the diﬀerent primary anbodies 
combinaons were incubated ON (48 hours for diﬀerenang EBs) at 4oC diluted in 
TBS++ (1x TBS, 0,1% Triton, 6% Donkey serum). Secondary anbody was incubated for 
2 hours at 37oC diluted in TBS++. Samples were analyzed on a confocal Leica SP5 AOBS 
microscope with Las AF (Leica Applicaon Suite Advanced Fluorescence) (Mar et al. 
2013). 
Teratoma immuno-characterizaon 
Teratomas were ﬁxed in 4% PFA for 4 hours and embedded in paraﬃn. 5μm secons 
were made using a microtome in a sequenal way, using at least three diﬀerent areas 
of each teratoma. Samples were incubated with citrate buﬀer pH9 for 1 hour at 103kPa 
for angen retrieval. Then, samples were incubated in blocking soluon for 30 minutes 
at RT and diﬀerent primary anbodies combinaons were incubated for 24 hours at 
4oC. Secondary anbody was incubated for 2 hours at 37oC diluted in TBS++. Samples 
were analyzed on a confocal Leica SP5 AOBS microscope with Las AF (Leica Applicaon 
Suite Advanced Fluorescence)(Mar et al. 2013). 
SNMs immunocharacterizaon 
SNMs were ﬁxed with 4% PFA for 75 minutes at 4oC and embedded in paraﬃn. Samples 
were cut in 5μm secons using a microtome and then were incubated with blocking 
buﬀer for 30 minutes at RT. Immunodetecon of MAP2 (Santa Cruz #sc-32791) and 
Tuj1 was performed by primary anbody incubaon for 24 hours at 4oC followed by 
secondary anbody incubaon for 2 hours at 37oC. For in toto protocol SNMs were 
ﬁxed with 4% PFA for 75 minutes at 4oC. Samples were incubated with blocking buﬀer 
for 2 hours at RT followed by ON incubaon at 4oC. Primary anbodies PAX6 (Covance 
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#PRB-278P), MAP2 and Tuj1, were incubated for 72 hours at 4oC and secondary an-
bodies were incubated 2 hours at RT, then ON at 4oC followed by 2 hours at RT. 
Samples were analyzed on a confocal Leica SP5 AOBS microscope with Las AF (Leica 
Applicaon Suite Advanced Fluorescence) 
Neuronal immunostaining 
iPSC derived neurons with dopaminergic diﬀerenaon protocol were characterized 
using primary anbodies an MAP2, PAX6, NeuN (Chemicon #MAB377), Neuroﬁlament 
(Sigma N4142), Synapsin, TH (Sigma T8700-1VL) and Tuj1. Samples were ﬁxed with 4% 
PFA for 30 minutes and incubated in blocking soluon for 30 minutes. Then diﬀerent 
primary anbodies combinaons were incubated ON at 4oC diluted in TBS++. Second-
ary anbody was incubated for 2h at 37oC diluted in TBS++. Samples were analyzed on 
a confocal Leica SP5 AOBS microscope with Las AF (Leica Applicaon Suite Advanced 
Fluorescence). 
Gaucher’s Disease phenotype immuno-characterizaon 
Slide ﬂasks containing neurons derived from GD iPSC were ﬁxed with 2% PFA for 20 
minutes then, samples were incubated in blocking soluon without triton (1x TBS, 6% 
Donkey serum) for 1 hour and then primary anbodies for neuronal and lysosomal de-
tecon were added such as GBA (Abcam #ab55080), Lamp2 (Abcam  #ab37024), Tuj1, 
TH and incubated for 72 hours at 4oC. Secondary anbody was incubated for 2h at 
37oC. An increment of the signal was needed for GBA primary anbody, so an extra 
incubaon for 2 hours at 37oC with an anbody an-FITC conjugated with Alexa 488 
(Invitrogen #A11090) was performed. Samples were analyzed on a confocal Leica SP5 
AOBS microscope with Las AF (Leica Applicaon Suite Advanced Fluorescence). 
Tay-Sachs phenotype immuno-characterizaon 
Slide ﬂasks containing neurons derived from TS iPSC were ﬁxed with 4% PFA for 20 
minutes. Samples were incubated in blocking soluon (1x TBS, 0,02% saponin, 6% Don-
key serum) for 1 hour. Phenotype characterizaon was performed by incubang the 
samples with primary anbodies against Tuj1, Lamp2 and GM2 (gi from Konstann 
Dobrenis) ON at 4oC. Secondary anbody was incubated for 2h at 37oC diluted in 
TBS++. Samples were analyzed on a confocal Leica SP5 AOBS microscope with Las AF 
(Leica Applicaon Suite Advanced Fluorescence). 
Transmission Electron microscopy 
TS diﬀerenated neurons were lied with AccuMax and pelleted. Samples were ﬁxated 
with a soluon of 2,5% Glutaraldehyde in cacodylate for 2 hours at 4oC. Post-ﬁxaon 
was made with 1% OsO4 in cacodylate for another 2 hours. Dehydraon of the samples 
was performed with increasing concentraons of ethanol, ﬁnishing with incubaon in 
propylene oxide. Sample embedding was done increasing concentraons of epoxy res-
in in propylene oxide followed by encapsulaon of the resin and polymerizaon at 60oC 
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for 48 hours. Samples were cut with an ultramicrotome in 80nm secons. Negave 
staining of the secon was made using uranyl acetate and lead (II) nitrate. Samples 
were observed at the JEOL JEM 1011 electronic microscope. 
 
 
Molecular Biology and Biochemistry 
Western blot analysis 
Cells from diﬀerenated and undiﬀerenated cultures were incubated in the presence 
or the absence of compounds 6S-ADBI-NJ or NOI-NJ (Luan et al. 2009). Aer indicated 
mes, the cells were harvested and equal amounts of cell lysate (30mg from Bradford-
determined RIPA homogenates) were separated by 10% SDS-polyacrylamide gel elec-
trophoresis and transferred onto Immobilon PVDF membranes (Millipore #IPVH00010). 
For immunochemical detecon, blots were incubated with primary anbodies an-GBA 
and an-acn. Subsequently incubated with secondary an-mouse IgG peroxidase-
conjugated anbody and developed with the chemoluminescence ECL plus (Amersham 
#RPN2132) detecon system. 
Acid-β-glucosidase enzymac acvity assay 
Acid-β-glucosidase acvity in cell pellets was determined as previously described 
(Cormand et al. 1997) with the ﬂuorogenic substrate  4-methylumbelliferyl-b-D-
glucopyranoside. Cellular pellet was resuspended in H2O followed by 3 freeze-thaw 
cycles of 10 minutes each. Then Lowry protein quanﬁcaon was performed. Samples 
were incubated for 1 hour at 37oC with the substrate at 5mM. Acvies were meas-
ured in triplicate in a Polarstar Omega A micro plate reader at 465nm emission. The 
results were presented as mean+SD. Student’s t-test was used to examine the signiﬁ-
cance of diﬀerences between group means, and the diﬀerences in P-values, 0.05 were 
considered signiﬁcant. 
Acid-β-glucosidase acvity in macrophages was measured by FACS as previously de-
scribed (van Es et al. 1997). Brieﬂy, 100.000 cells were incubated with 1mM FDGlu at 
25oC for 45 minutes. Speciﬁcity of the assay was conﬁrmed by the use of 1mM CBE, a 
GBA irreversible inhibitor. 
β-Hexosaminidase A enzymac acvity assay 
HexA enzymac acvity was determined by measuring 4-methyllumbelliferone hydrol-
ysis from the substrate. Cellular pellet was resuspended in H2O followed by 3 freeze-
thaw cycles of 10 minutes each. Then Lowry protein quanﬁcaon was performed. 
Samples were incubated for 1 hour at 37oC with the substrate at 1mM. Acvies were 
measured in triplicate in a Polarstar Omega A micro plate reader at 465nm emission. 
The results were presented as mean+SD. Student’s t-test was used to examine the sig-
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niﬁcance of diﬀerences between group means, and the diﬀerences in P-values, 0.05 
were considered signiﬁcant. 
CD proﬁle analysis  
Cells were stained with monoclonal anbodies against human CD11b (BD Biosciences), 
CD14 (BD Biosciences), CD33 (BD Biosciences), CD163 (R&D systems) conjugated with 
ﬂuorescein, phycoerythrin or allophycocyanin according to the manufacturer’s instruc-
ons and analyzed by using Moﬂo high-performance cell sorter and ﬂow cytometry 
analyzer Gallios. PI-stained dead cells were gated out. Human cell populaon was iden-
ﬁed upon staining with anbodies against the pan-human marker TRA-1-85 (BD Bio-
sciences). 
 
RT-qPCR 
Total RNA was extracted with Trizol (Invitrogen #15596-026) following manufacturer’s 
protocol. cDNA was performed with the Cloned AMV First-Strand cDNA Synthesis Kit 
(Invitrogen #12328-040), using random hexamers. SYBR Green (Sigma #S4438) detec-
on system was used in the RT-qPCR. RT-qPCR reacon was run in a 7900HT fast real 
me PCR system from Applied Biosystems. Speciﬁc primers were designed with Primer 
express soware.  
 
Mutaon analysis 
Genomic DNA was extracted using DNeasy Blood & Tissue kit (Qiagen #69504). Primers 
for mutaon analysis were designed ﬂanking the mutaon site in the genome. Se-
quencing was performed using Big Dye Terminator v3.1 Cycle kit (Invitrogen #4337455) 
hGAPDH  FP GCACCGTCAAGGCTGAGAAC hEndo-C-MYC FP CGGGCGGGCACTTTG 
hGAPDH RP AGGGATCTCGCTCCTGGAA hEndo-C-MYC RP GGAGAGTCGCGTCCTTGCT 
hEndo-OCT4 FP GGGTTTTTGGGATTAAGTTCTTCA Nanog FP ACCAGAACTGTGTTCTCTTCCACC 
hEndo-OCT4 RP GCCCCCACCCTTTGTGTT Nanog RP CCATTGCTATTCTTCGGCCAGTTG 
hEndo-SOX2 FP CAAAAATGGCCATGCAGGTT Rex1 FP GCGTACGCAAATTAAAGTCCAGA 
hEndo-SOX2 RP AGTTGGGATCGAACAAAAGCTATT Rex1 RP ATCCTAAACAGCTCGCAGAAT 
hEndo-KLF4 FP AGCCTAAATGATGGTGCTTGGT DNMT3B FP TGCTGCTCCAGGGCCCGATA-CTTC 
hEndo-KLF4 RP TTGAAAACTTTGGCTTCCTTGTT DNMT3B RP TCCTTTCGAGCTCAGTGCACCA-CAAAAC 
Table 2. Primers used in the qPCR por detecon of pluripotency markers 
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and samples were analyzed in a capillary sequencer (Applied Biosystems 3730xl or 
3130xl DNA analyzer). GDExon7FP ATTCACCGAGCCCTGCAGTT GDExon7RP 
TTCACAAAGTATCTGGCCC; GDExon11FP AAGTTCATTCCTGAGGGCT GDExon11RP 
GTTTAGCACGACCACAACAG; TSExon11FP GATTCAGCCAGACACAATCA TSExon11RP 
CTCACCCCAGCTAAGTTGTT 
 
iPSC authencaon 
GD and TS ﬁbroblasts and derived iPSC samples were sent to qgenomics (hp://
www.qgenomics.com) in order to genotype STR markers: TH01, D21S11, D5S828, 
D13S317, D7S820, D16S539, CSF1PO, vWa y TPOX. The combinaon of these nine 
markers produces an allele proﬁle with a 1 in 2.9x109 probability of coincidence. 
Brieﬂy, genomic DNA was extracted, a mulplex PCR with speciﬁc primers for the 
above STR markers followed by an electrophoresis and allele analysis.  
 
Microarray processing and analysis 
RNA was extracted using the miRNeasy Mini kit (Qiagen) following manufacturer’s indi-
caons. RNA integrity was assessed using an Agilent 2100 bioanalyzer. All samples had 
high integrity (RNA integrity number (RIN) ≥8.7) and were subsequently used in micro-
array experiments. Ampliﬁcaon, labeling and hybridizaons were performed accord-
ing to the protocols from Ambion and Aﬀymetrix. Brieﬂy, 200ng of total RNA were am-
pliﬁed using the Ambion WT Expression Kit, labeled using the WT Terminal Labeling Lit 
of Aﬀymetrix, and then hybridized to Human Gene 1.0 ST Array of Aﬀymetrix, in a 
GeneChip Hybridizaon Oven 640. Washing and scanning were performed using the 
hybridizaon Wash and Stain Kit and the GeneChip System of Aﬀymetrix (GeneChip 
Fluidics Staon 450 and Gene-Chip Scanner 3000 7G). 
Microarray data analysis was performed as follows: aer quality control of raw data, it 
was background corrected, quanle-normalized and summarized to a gene level using 
the robust mul-chip average (RMA) (Irizarry et al. 2003) obtaining a total of 28 832 
transcript clusters, excluding controls, which roughly correspond to genes. NetAﬀx an-
notaons (version 32, human genome 19) were used to annotate analyzed data.  
Hierarchical cluster analysis was performed to see how data aggregate and a heat map 
was generated with pluripotency genes. All data analysis was performed in R (version 
2.15) with packages aroma.aﬀymetrix (Bengtsson et al. 2008), Biobase, Aﬀy, biomaRt 
and gplots. Ingenuity Pathway Analysis v9.0 was used to perform funconal analysis of 
the results. 
 
Reprogramming vector 
The reprogramming vector consisted of a linear 10kb DNA fragment containing a 
polycistronic reprogramming cassee ﬂanked by LoxP sites in order to allow removal of 
the cassee once the reprogramming is complete. Oct4, Sox2, Klf4, c-Myc and GFP 
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were linked through 2A self-cleaving pepdes conforming the polycistron which ex-
pression is driven by a CAG promoter (Fig 5) 
 
Southern blot 
5μg of genomic DNA was digested with PstII and EcoRI (New England Biolabs), runned 
in a 1% agarose gel at low voltage and transferred to a posively charged nylon mem-
brane by capillarity. Probes were designed both internal and external to the LoxP-
ﬂanked segment of the construct and were labeled with the PCR DIG probe synthesis 
kit following manufacturer’s protocol. Hybridizaon of the probes was made ON at 
65oC. Membranes were incubated with anbodies an-DIG and development was 
made using CDP-Star chemoluminescent substrate. 
 
Lenvirus expressing GBA1 or HEXA 
GBA1 and HEXA genes were introduced separately in a typical VIH derived lenviral 
backbone vector containing cis-acng sequences required for the retro-transcripon 
and packaging of the vector. The 3’LTR has a deleon on the promoter-enhancer region 
making it a self-inacvang vector. The transgene is controlled by human β acn/ RU5 
promoter and is followed by a WPRE sequence in order to confer stability to the RNA 
(Fig6) 
 
Lenvirus expressing Cre recombinase 
Cre recombinase was introduced in a typical VIH derived lenviral backbone vector 
containing cis-acng sequences required for the retro-transcripon and packaging of 
the vector. On the 3’LTR there is a LoxP site, so when Cre is expressed, the cassee is 
removed from the genome.  
Fig 5. Reprogramming cassee 
Fig6. Lenvirus expres-
sing HEXA or GBA schema 
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The 3’LTR has a deleon on the promoter-enhancer region making it a self-inacvang 
vector. Cre is controlled by CMV promoter and is followed by a WPRE sequence in or-
der to confer stability to the RNA (Fig7)  
 
Packaging vectors 
Third generaon lenviral vector systems consists of 4 plasmids. One is the lenviral 
backbone with the transgenes and the other 3 plasmids supply the trans elements 
needed for the retro-transcripon and packaging of the vector. 
Vector pVSV-G carries the VSV-G gene, which encodes for a protein in the viral enve-
lope responsible for the viral tropism. VSV-G is under the control of a CMV promoter. 
Vector pRev carries the Rev protein which recognizes 
RRE in the viral mRNA and exports it to the cytoplasm. 
Vector pMDL carries Gag-Pol precursor which is pro-
cessed into an integrase, the reverse transcriptase 
and structural proteins. Non integrave lenviral vec-
tors were made with a pMDL vector which encodes 
for a Gag-Pol precursor which has an Asp64Val muta-
on on the integrase gene (Fig8). 
 
Fig7. Lenvirus expressing 
Cre schema 
Fig8. Packaging vectors schema 
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I. iPSC derivaon and characterizaon 
iPSC derivaon can be performed from a number of diﬀerent cell types by delivery of a 
combinaon of reprogramming factors to the cells through several alternave meth-
ods. In this work, the cells of choice were primary ﬁbroblasts obtained from a biopsy of 
a paent diagnosed with GD type II carrying a compound heterozygote genotype 
(p.L444P/ p.G202R) and primary ﬁbroblasts from a paent diagnosed with TS, obtained 
from the Coriell Cell Repository (#GM00527; p.W420C/ IVS11+1G>A). Reprogramming 
factors delivery was by nucleofecon of a linear DNA fragment containing a polycistron 
expressing the pluripotency factors (Oct4, Sox2, Klf4, c-Myc) and GFP as reporter, all 
linked by 2A self-cleaving pepdes and under the control of CAG promoter. The ex-
 Fig 9. Reprogramming cassee delivery and eliminaon: A) Southern blot analysis of GD and TS iPSc lines (G1-G7 and 
TS1-TS7) with 5´probe. B) Southern blot analysis of GD and TS iPSC before and aer delivery of CRE recombinase with 
either 3´probe or 5´probe.  C) Schemac representaon of reprogramming construct and reprogramming cassee 
eliminaon strategy. D) 10x magniﬁcaon photos of GFP ﬂuorescence iPSC. Upper panel, before delivery of CRE re-
combinase and lower panel aer delivery of CRE recombinase. 
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pression cassee was ﬂanked by LoxP sites, allowing its removal by Cre recombinase 
delivery once reprogramming was complete (Fig9). 
WT and TS GFP posive colonies with ESC-like morphology appeared around 4 weeks 
aer nucleofecon. GD colonies suﬀered a noceable delay and appeared aer 5 to 6 
weeks. Seven GD and seven TS colonies were isolated and expanded. Some iPSC lines 
silenced the reprogramming cassee spontaneously aer 8 – 12 passages as judged by 
Fig10. iPSC pluripotency characterizaon: Upper panel, Immunostaining with diﬀerent pluripotency markers (20x). 
Morphology of the resulng colonies and AP staining (10x). Lower panel: qPCR for expression of pluripotency factors.  
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GFP expression, while others remained GFP posive, indicang persistence of 
transgene expression. In order to remove the reprogramming cassee, iPSC lines show-
ing GFP expression were transduced with a non-integrave lenviral vector expressing 
Cre recombinase and cherry ﬂuorescent protein as a reporter and plated over an irHFF 
feeder layer. Aer three days, cherry posive pluripotent cells were isolated by FACS, 
replated and expanded, leading to the establishment of subclones which showed no 
GFP expression (suggesng loss of the transgene) and no Cherry expression (suggesng 
no integraon of the lenviral vector used to deliver CRE recombinase). Southern blot 
analysis conﬁrmed that loss of GFP expression was due to the excision of the repro-
gramming cassee (Fig9).  
In order to establish that the iPSC lines isolated were truly pluripotent, an exhausve 
characterizaon was performed. GD and TS iPSC lines showed similar morphology to 
hESC ES4 cell line and maintained their characteriscs over long-term culture. Pluripo-
tency of the iPSC derived cell lines was con-
ﬁrmed by alkaline phosphatase acvity, immu-
nodetecon of speciﬁc pluripotency markers 
(Oct4, Sox2, Nanog, Tra1-60, Tra1-81, SSEA3 
and SSEA4) and by real-me qPCR expression 
analysis of pluripotency associated genes 
(Oct4, Sox2, Klf4, c-Myc, DNMT3B, Nanog and 
Rex1) (Fig10). In order to check that the delay 
in the reprogramming of GD did not aﬀect its 
pluripotent condion, GD iPSC pluripotency 
was further analyzed by FACS and by 
microarray gene expression (Fig11 and 
Fig12).  
 Fig11. Trascriponal proﬁling by microarray analy-
sis. GD ﬁbroblasts from a paent, two WT ﬁbroblast 
populaons, hESC 4, GD iPSC lines (iPSC-GD-C21 
and iPSC-GD-A8) and a WT iPSC line. 
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Pluripotency is the capability of a cell to diﬀerenate into any cell type of the organism. 
Pluripotency can be demonstrated by in vitro or in vivo diﬀerenaon (teratoma for-
maon). Typically, this involves detecon of at least two markers from each germ layer 
(ectoderm, mesoderm and endoderm). Increasingly stronger levels of proof are aﬀord-
ed by chimera formaon, germline transmission and tetraploid complementaon, 
which demonstrate the potenal of an iPSC line to develop into a complete organism. 
For ethical reasons, in the human system, demonstraon of pluripotency is necessarily 
limited to in vitro diﬀerenaon and teratoma formaon. GD and TS  iPSC showed full 
diﬀerenaon capacity when they were induced to diﬀerenate in vitro to the three 
Fig12. Cytometry analysis of pluripotency in hESC 4, WT iPSC  and GD iPSC C21 and A8.  
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germ layers, expressing typical markers of endoderm (FOXA2, AFP), mesoderm (ASMA 
and ASA), and ectoderm (Tuj1 and GFAP).  GD and TS iPSC were also injected into SCID-
beige mice and formed teratomas, which presented in vivo diﬀerenaon detected by 
immunohistochemistry with the same markers already described for the in vitro diﬀer-
enaon to the three germ layers (Fig13). 
A karyotype analysis was performed to evaluate genomic integrity aer reprogram-
ming. TS iPSC lines presented a normal karyotype; GD iPSC lines presented an inversion 
in the 12th chromosome. In addion, veriﬁcaon that the TS and GD iPSC lines were 
indeed derived from the original TS and GD ﬁbroblasts was performed by STR genotyp-
ing (Fig14) 
 
 
 
 
Fig13. In vitro diﬀerenaon (ectoderm 20x, mesoderm 40xTS WT 20xGD, endoderm 40x) and  teratoma for-
maon (ectoderm 40xTS WT 20xGD, mesoderm 40x, endoderm 40x) analyzed by immunohistochemistry. 
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II. Disease phenotype characterizaon 
Disease models, by deﬁnion, must recapitulate disease phenotype at the molecular 
and cellular levels if they are to be useful for basic mechanisc studies or therapy de-
velopment. Therefore, the characterizaon of the disease phenotype in the obtained 
iPSC and diﬀerenated disease relevant cell types was needed.  
Gaucher phenotype 
First, it was conﬁrmed that the GD iPSC derived contained the same GD mutaons 
(c.721 G>A and c.1448 T>C) reported in the original ﬁbroblasts they were derived from 
Fig14. Authencaon and karyotype: Upper panel: karyotype analysis of GD C21 and TS A3 iPSC. Lower panel: 
Results of cell authencaon analysis, TS ﬁbroblasts and TS iPSC in one hand and GD ﬁbroblasts and GD iPSC in 
the other, match perfectly, indicang that the derived iPSC lines come from the analyzed ﬁbroblasts. 
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(Fig15). Second, enzymac acvity assays for GBA were performed in WT or GD cells 
for both the inial ﬁbroblasts and the iPSC derived from them (Fig15). GBA acvity was 
clearly reduced in GD ﬁbroblasts compared to WT ﬁbroblasts (GD ﬁbroblasts had only 
1,91% of the GBA acvity found in WT ﬁbroblasts). In both WT and GD iPSC, GBA acvi-
ty was reduced compared to that found in the corresponding ﬁbroblasts, but GBA ac-
vity was sll lower in 
GD iPSC in comparison 
to WT iPSC (GD iPSC 
showed only 14,55% of 
the acvity expressed 
by WT iPSC). In order to 
determine whether the 
lower GBA acvity in GD 
cells could be parally 
due to lower GBA pro-
tein levels, western blot 
analysis was performed 
which indeed showed lower steady state levels 
of GBA protein in GD cells (Fig15). 
In order to check that possible diﬀerences in ge-
nec background between WT and GD iPSC 
could aﬀect the results, congenic GD iPSC lines 
rescued for GBA expression were established by 
transducing them with a lenviral vector ex-
pressing WT GBA1 gene and isolang subclones. 
This strategy led to the establishment of four 
Fig15. A) Mutaon detecon in GD-iPSC C21 B) Acid-b-glucosidase acvity in wt vs. 
GD cells in ﬁbroblasts (P=0,0024) and iPSC (P=0,0074). C) Western blot analysis of 
WT iPSC N17 and N22, GD iPSC A8 and C21.  
Fig16. Genec rescue of GD iPSC C21 with 
lenviral vector expressing GBA1. Acid-b-
glucosidase enzymac acvity levels in WT, 
GD and 4 rescued lines 
  
 56 
corrected subclones, three of which had similar or higher levels of GBA acvity than 
those found in WT iPSC (Fig16). 
Having established that GD iPSC show lower GBA protein levels and acvity, the basic 
biochemical feature of GD, the next step was to diﬀerenate GD iPSC to the main cell 
types typically aﬀected by the disease. In all types of GD, one of the aﬀected cell types 
are macrophages which, due to glucocerebroside accumulaon, are transformed in 
Gaucher cells, accumulang in diﬀerent ssues and being responsible for many of the sys-
temic aspects of the disease. Our GD iPSC were derived from a paent diagnosed with the acute 
neuronopathic form of the disease, in which neurons are also damaged by glucocerebroside 
accumulaon, impairing their funcon and leading to neuron degeneraon. Because of 
it, GD iPSC were diﬀerenated to macrophages and neurons. 
Macrophages 
For the diﬀerenaon to macrophages two cell lines were used: the GD C21 and the 
corrected GD iPSC L-GBA 3-15, which had GBA acvity levels similar to that of WT iPSC. 
The protocol used was a combinaon of the diﬀerenaon protocols used by Raya et al 
(Raya et al. 2009) for obtaining HSC from human iPSC and that used by Choi et al (Choi 
et al. 2011) for mature myeloid cells derivaon from human pluripotent stem cells with 
some modiﬁcaons. Brieﬂy, iPSC were cultured as EBs, diﬀerenated to the hemato-
poiec lineage by co-culture on OP9 stromal cells and growth factor treatment for 14– 
17 days, and subjected to two successive macrophage inducing cytokine cocktail re-
gimes for 2 and 10 days, respecvely, as described in Materials and Methods secon.  
The resulng populaon derived from GD C21 iPSC was analyzed by FACS and showed 
expression of typical markers from the monocyte-macrophage lineage:  CD11b (18.3%), 
CD14 (35.6%), CD33 (35.5%) and CD163 (13.6%) (Fig17). The analysis also concluded 
that there were populaons expressing more than one marker from the monocyte-
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macrophage lineage: CD14 plus CD11b (17.1%), CD33 plus CD11b (20.1%) and CD14 
plus CD163 (14.7%) (Fig17). Macrophages produced with the above protocol were 
proved to be funconal macrophages as ascertained by phagocytosis of ﬂuorescent 
Fig17. Characterizaon of macrophages derived from GD iPSC C21 and recued L-GBA 3-15. A) Histograms show-
ing % of cells posive for monocyte-macrophage lineage markers CD11b, CD163, Cd14 and CD33 B) Scaer plots 
showing % of double posive cells for monocyte-macrophage lineage markers CD14/CD11b, CD33/CD11b and 
CD14/CD163. 
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opsonized beads (Fig18). The 
resulng populaon derived 
from the corrected sub-clone L-
GBA 3 – 15 showed an overall 
similar paern of marker expres-
sion: CD11b (11.7%), CD14 
(19.2%), CD33 (21%), CD163 
(8.4%); CD14 plus CD11b (11%), 
CD33 plus CD11b (12%), and 
9.6% of the cells expressing 
CD14 plus CD163 (9.6%) (Fig17).  
GBA acvity of the macrophages 
obtained from GD C21 and L-
GBA 3-15 iPSC was analyzed by 
FACS together with CD14 mark-
er. As expected, GD C21 iPSC 
derived macrophages showed 3 
to 6 mes less GBA than L-GBA 
3-15, in accordance with the 
GBA acvity observed, which 
was higher in the corrected 
macrophages than in the GD.  
In conclusion, funconal macrophages were obtained, concluding that diminished GBA 
expression and acvity levels do not aﬀect macrophage diﬀerenaon in vitro. 
 
Fig18. Comparison of macrophages derived from GD iPSc vs. genecally 
rescued GD iPSC. A) Phagocytosis assay: micrographs showing morpholo-
gy, ﬂuorescent beads, DAPI stain and merge of iPSC derived macrophages 
aer internalizaon of ﬂuorescent beads (40x).B) Scaer plots showing % 
of high expressing GBA1 cells and GBA acvity C) Histograms showing % 
of high expressing GBA1 cells and GBA acvity D) Bar chart showing quan-
ﬁcaon of % of high expressing GBA1 cells and mean ﬂuorescence (n=2).  
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Dopaminergic neurons 
As GD type II has a strong neuronopathic component, diﬀerenaon to neuronal types 
is crucial to the usefulness of the model. A previously described protocol for derivaon 
of dopaminergic neurons from ESC (Cho et al. 2008a) was chosen for the analysis of the 
phenotype in the iPSC derived neurons. This protocol has been shown to produce a 
high percentage of mature dopaminergic neurons capable of electrophysiological acv-
ity (Cho et al. 2008b) and consists in the formaon of spherical neural masses (SNMs) 
that can be expanded and subsequently diﬀerenated to dopaminergic neurons using 
a combinaon of N2, B27, ascorbic acid and the mid-brain paerning factors FGF8 and 
SHH (Fig. 19) 
Fig19. Dopaminergic neuron derivaon from iPSC GD, TS and WT. Pictures are representave for all lines. Rows 
from top to boom: iPSC, SNM, diﬀerenang SNM (20x) and mature dopaminergic neurons (40x). Markers 
indicated in each panel.  
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Wild type, GD C21 and L-GBA 3-15 iPSC were diﬀerenated with this protocol. SNMs 
obtained from the cell lines were analyzed by immunoﬂuorescence, showing expres-
sion of neural lineage (Tuj1) and neural precursor markers (Pax6, Map2). At the end of 
the protocol, slides were analyzed by immunoﬂuorescence, resulng in heterogeneous 
cultures with neuronal morphology expressing Tuj1 marker. A signiﬁcant percentage of 
TUJ1+ neurons were also posive for tyrosine hydroxylase (TH), a marker of dopamin-
ergic neurons. In addion, clusters of mature neurons posive for neuroﬁlament, syn-
apsin and NeuN were found (Fig23). Nevertheless, Map2 marker was also found in the 
majority of neurons, indicang heterogeneity of diﬀerent developmental stages in the 
resulng populaon. 
No signiﬁcant diﬀerences in diﬀerenaon ability between the three lines were ob-
served, suggesng that GBA expression levels have lile eﬀect on the diﬀerenaon 
process; yield and proporon of mature neurons. While the diﬀerenaon protocol 
was generally reproducible, yields were variable from experiment to experiment for all 
three lines used, presumably due to stochasc events and subtle variaon in culture 
parameters. 
The iPSC derived neurons 
were further analyzed in 
order to check the recapitu-
laon of the GD phenotype. 
Neurons were subjected to 
western blot analysis and 
for GBA acvity assays as 
described in the material 
and methods chapter. Neu-
rons derived from GD C21 
Fig20. GBA characterizaon in diﬀerenated neurons derived from iPSC and 
hES A) GBA acvity B) Western blot detecon for GBA  
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iPSC showed less GBA acvity than those derived from WT iPSC and this result was co-
herent with the GBA protein levels as seen in the western blot results (Fig20) 
Tay Sachs phenotype 
The TS ﬁbroblast line ulized to derive iPSC has a compound heterozygote genotype 
consisng of one allele with a mutaon in exon 11 (c.1260 G>C) which leads to an ami-
noacid substuon (Trp420Cys), 
and the second allele carrying the 
intronic mutaon IVS11+1 G>A, 
which leads to a splice site muta-
on, altering normal RNA pro-
cessing (Miranda et al. 1994). The 
presence of both mutaons was 
conﬁrmed by sequencing in both 
ﬁbroblasts and iPSC (Fig21). An 
enzymac acvity assay was per-
formed in the inial ﬁbroblasts 
and in the derived iPSC. HexA ac-
vity was clearly reduced in both 
TS ﬁbroblast and iPSC compared 
to WT (Fig21). 
TS disease phenotypes in TS iPSC were analyzed and compared to both WT iPSC and 
with TS iPSC that had been rescued by transducon with a lenviral vector expressing 
the WT HEXA gene. As in the case of GD, this allowed for the development of an iso-
genic cell line pair allowing comparison of the WT and mutated TS alleles in an other-
wise idencal genec background. TS iPSC were transduced with a lenviral vector ex-
Fig21. iPSC TS characterizaon. Le panel: b-Hexosaminidase A 
acvity in WT vs. TS cells in ﬁbroblasts and iPSC. Right panel: 
Mutaon detecon in TS-iPSC A3 
  62 
 
pressing the wild type form of the HexA gene, 
providing full enzymac acvity to the HexA en-
zyme heterodimer. This correcon led to the es-
tablishment of four corrected subclones, two of 
which had similar or higher levels than WT iPSC 
(TS L-HexA 3-1 and TS L-HexA 3-3) (Fig22).  
Clinical manifestaons in TS are almost exclusive-
ly neurologic and the pathology is restricted to 
the nervous system. GM2 is mainly found on the 
gray maer of the brain, forming part of the plas-
ma membranes of the neurons. For GM2 degrada-
on, the plasma membrane containing glycosphingolipids is endocytosed, passing 
through the endosomal compartments which ﬁnally lead to lysosomes. In the lack of 
HexA enzyme, GM2 cannot be degraded and it accumulates on the lysosome, impairing 
cell funcon and leading to brain damage (Gravel et al. 2001). Because of this, diﬀeren-
aon to neuronal cells is fundamental in the phenotype characterizaon of TS dis-
ease. As TS hallmarks (enlarged lysosomes and mulllamelar bodies in the cytoplasm) 
are found in all neuronal types and diﬀerenaon to dopaminergic neurons protocol 
was already set up, TS iPSC were derived to neuronal lineage using the same protocol 
that was used with the GD iPSC for dopaminergic neuron derivaon. 
Wild type, TS A3 and TS L-HexA 3-1 were diﬀerenated to the neuronal lineage with 
the Cho protocol and, as in the case of GD, SNMs obtained from the cell lines were ana-
lyzed by immunoﬂuorescence, showing expression of neural lineage (Tuj1) and neural 
precursor markers (Pax6, Map2). Final slides were analyzed by immunoﬂuorescence, 
showing the same characteriscs as in the GD case: heterogeneous cultures with neu-
ronal morphology expressing Tuj1 marker, in which a signiﬁcant percentage was posi-
Fig22. Genec rescue of TS iPSC A3 with len-
viral vector expressing HexA. b-
Hexosaminidase  enzymac acvity levels in 
WT, TS and 4 rescued lines 
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ve for dopaminergic marker TH. Also, heterogeneous development stages were found 
as indicated by the presence of Map2 marker as well as neuroﬁlament, synapsin and 
NeuN (Fig23).  
Wild type, TS A3 and TS L-HexA 3-1 showed similar diﬀerenaon ability, suggesng 
that HexA acvity is not crucial for the neuronal development and that GM2 accumula-
on does not impair it. However, as in GD, diﬀerenaon results were reproducible 
but variable from experiment to experiment for all three lines, without a noceable 
bias for any of the cell lines, underlying the heterogeneity present on the diﬀerena-
on protocols.   
One typical characterisc in TS is the accumulaon of GM2 and cholesterol in the sec-
ondary lysosomes of the neurons of both central nervous system and peripheral nerv-
ous system. This is easily observable by immunostaining of GM2 ganglioside and the 
Fig23. Analysis of mature neurons derived from GD, TS and WT iPSC. Pictures are representave for all lines (40x). 
Markers indicated in each panel. 
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lysosomal marker Lamp2. Thus, for TS phenotype characterizaon, wild type, TS A3 and 
TS L-HexA 3-1 derived neurons were analyzed by immunoﬂuorescence of neuronal 
marker Tuj1 together with Lamp2 and ganglioside GM2, revealing an enlargement and 
increasing the number of the lysosomes in the TS A3 derived neurons, comparing to 
wild type and the corrected TS L-HexA 3-1 (Fig24). Also it is observable an increase in 
the GM2 ganglioside in the TS A3 derived neurons compared to wild type and correct-
ed. TEM on paents’ brains reveals that the neuronal cytoplasm is full with mulllame-
Fig24. Phenotype characterizaon of derived neurons from TS iPSC A3. A) Fluorescence microscopy images (40x) 
showing Lamp2 (lysosome marker) GM2 and Tuj1. B) Transmission electron microscopy on WT and iPSC neurons. 
Arrows mark lysosome ultrastructures. 
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lar membranous bodies (MCBs) which correspond to the secondary lysosomes contain-
ing accumulaon of GM2 (Terry et al. 1963). TEM analysis on the wild type and TS A3 
derived neurons recapitulates the ultrastructure observed on paents’ brains, showing 
MCBs in the cytoplasm of TS A3 neurons and not in the WT (Fig24). 
 
III. Using GD and TS iPSC derived neurons for small compound 
tesng 
Gaucher Disease and chemical chaperones. 
GD can be treated with splenectomy, blood transfusions and analgesics, but these are 
directed to the alleviaon of the symptoms rather than to eliminate the cause of the 
disease. Systemic aspects of the disease could be addressed by bone marrow trans-
plantaon, in which the ﬁnd of a compable donor is the liming factor; or by gene 
therapy, delivering the GBA1 gene to hematopoiec stem cells, but because of its asso-
ciated risk, it is not currently a method used in the clinic. The most used GD treatments 
involve ERT, SRT and recently it has been added the use of pharmacological chaper-
ones.  ERT consists in a regular intravenous infusion of a modiﬁed GBA with N-
acetylglucosamine and mannose residues so it can be incorporated into the paent’s 
macrophages (Barton et al. 1991; Beutler 2004; Aviezer et al. 2009). SRT is directed to 
reduce the GBA substrate, the  glucosylceramide, by inhibing the glucosyltransferase 
with the use of imino sugars as the N-butyldeoxynojirimycin (NB-DNJ) (Pla et al. 1994; 
Cox et al. 2000; Buers et al. 2005; Aerts et al. 2006; Elstein et al. 2009). Both strate-
gies have demonstrated to be eﬀecve treang the systemic aspect of the disease 
(Schiﬀmann et al. 1997; Grabowski et al. 1998; Pla et al. 2001; Weinreb et al. 2002), 
but none is able to cross the blood brain barrier with enough eﬃciency to have any 
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impact on the neuronal aspects of the disease (Prows et al. 1997; Aerts et al. 2006; Be-
nito et al. 2011).  
Pharmacological chaperones are based in GBA inhibitors which use at sub-inhibitory 
concentraons leads to the stabilizaon of the GBA structure, protecng it from prem-
ature degradaon and facilitang its traﬃcking through the ER to the lysosome. On the 
lysosome, the glucosylceramide concentraon displaces the complex enzyme-inhibitor 
to enzyme-substrate, recovering the GBA acvity (Yu et al. 2007; Paren 2009; Benito 
et al. 2011). In this respect, the use of imino sugar-based scaﬀolds as N-(n-nonyl)
deoxynojirimycin (NN-DNJ), increased the GBA acvity in mutant forms p.N370S and 
p.G202R (Sawkar et al. 2002; Sawkar et al. 2005), but also resulted in an inhibitor of 
both α and β glucosidases, which could lead to secondary eﬀects (Suzuki et al. 2007). 
Recently, bicyclic nojirimycin analogues with sp2 imino sugar structure were found to 
be highly selecve compeve inhibitors of GBA but no other glucosidases (Luan et al. 
2009). Their chaperoning eﬀects were characterized in GD ﬁbroblasts, but not in GD 
neurons, oﬀering the perfect framework to validate the iPSC-GD model as a drug 
tesng pla	orm by analyzing the eﬀect of the bicyclic nojirimycin analogues in the de-
rived neurons from the iPSC-GD lines.  
Inially, ﬁve bicyclic nojirimycin analogues were chosen and tested on WT and GD ﬁ-
broblasts. Compounds were added to the culture media for 4 days, using diﬀerent con-
centraons from 0 to 100 μM and then GBA acvity was analyzed. Three of the com-
pounds (6S-NOI-GJ, 6S-NOI-NJ and 6N-NOI-NJ) were able to increase the GBA acvity 
on the GD ﬁbroblasts, but inhibited its acvity in WT ﬁbroblasts (Fig25). The other two 
compounds (NOI-NJ and 6S-ADBI-NJ) performed an increase on GBA acvity on GD ﬁ-
broblasts of 2-4 fold change comparing to untreated GD ﬁbroblasts without having a 
negave eﬀect on the WT ﬁbroblasts (Fig25). Because of this, the eﬀect of the com-
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pounds on the GBA acvity of the derived neurons was focused on these two com-
pounds: NOI-NJ and 6S-ADBI-NJ.   
For tesng the NOI-NJ and 6S-ADBI-NJ compounds in GD derived neurons, diﬀerent 
iPSC lines (WT, iPSC GD C21 and GD L-GBA 3-15) were diﬀerenated to dopaminergic 
neurons following the protocol used before (Cho et al. 2008a). On the last four days of 
Fig25.  Acid-b-glucosidase enzymac acvity levels in WT and GD ﬁbroblasts treated with the diﬀerent bicyclic nojiri-
mycin analogues 
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diﬀerenaon, 30μM of either NOI-NJ or 6S-ADBI-NJ were added to the media. The 
addion of the compounds did not aﬀect the eﬃciency or yield of diﬀerenaon result. 
Protein extracts from treated and untreated iPSC derived neurons from both WT, GD 
iPSC and corrected GD L-GBA 3-15 were analyzed for GBA protein levels and acvity. 
NOI-NJ and 6S-ADBI-NJ treated GD neurons show increased GBA acvity by 3-4 fold 
compared to untreated GD neurons 
(Fig26). An increase of acvity was 
also noceable in both treated WT 
and corrected L-GBA 3-15 neurons. 
These results are consistent with 
the increase of protein levels ob-
served in the treated WT, GD and 
corrected neurons in the western 
blot analysis (Fig26), suggesng that 
the increase of GBA acvity is due 
to an increase of the protein levels. 
Together, these results suggest that 
both compounds were able to in-
crease the GBA stability and im-
prove its traﬃcking to the lysosomes.   
Tay Sachs and the exocytosis strategy 
There have been studies for Tay Sachs therapy which involve ERT; unfortunately they 
have not been successful mainly due to the diﬃculty of the enzyme to cross the BBB 
and target neuronal cells (Johnson et al. 1973; von Specht et al. 1979). Miglustat (N-
butyldeoxynojirimycin or NB-DNJ) has been studied as a possible agent for SRT in TS, 
but despite its promising results in mice models (Pla et al. 1997; Baek et al. 2008), 
Fig26. Acid-b-glucosidase protein and enzymac acvity levels 
in diﬀerenated dopaminergic neuronal cultures derived 
from WT, GD, and L-GBA corrected GD iPSC subjected to 
30uM of 6S-ADBI-NJ and NOI-NJ 
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results have not been reproduced in human paents (Maegawa et al. 2009; Shapiro et 
al. 2009). Also, design and treatment with pharmacological chaperones is ongoing 
(Rountree et al. 2009; Clarke et al. 2011; Osher et al. 2011) for structural mutants in 
which the heterodimer HexA cannot be transported to the lysosome, not being useful 
for acvity mutants in which the HexA heterodimer is formed, able to be transported 
to the lysosome but that cannot degrade the GM2, so pharmacological chaperones may 
have an eﬀect on determinate mutants but are not applicable to all TS paents.  
Fig27. Neurons derived from WT, TS A3 and TS L-HexA 3-1 treated with 10uM of NCGC00250218-01 
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 A new approach for lysosomal storage diseases is the promoon of the exocytosis of 
the lysosomes and its content, reducing the negave eﬀect of the lipid accumulaon on 
the cell machinery (Klein et al. 2005; Medina et al. 2011). Parcularly, δ-tocopherol has 
probed to reduce lysosomal cholesterol accumulaon and decrease the lysosome vol-
ume by promong exocytosis in Niemann-Pick type C and Wolman disease (Xu et al. 
2012). In the same work, δ-tocopherol was also tested in ﬁbroblasts of other six lysoso-
mal storage diseases including TS. Access to relevant human cell types in TS for drug 
tesng is diﬃcult, but the iPSC-TS model presented in this defense oﬀer a pla	orm for 
obtaining human neuronal cells in which δ-tocopherol and its analogue can be tested. 
Two compounds were tested one is 
δ-tocopherol (NCGC00160622-03) 
and the other is a metabolically 
stable δ-tocopherol analogue 
(NCGC00250218-01). Neurons 
were derived from WT, TS A3 and 
TS L-HexA 3-1 iPSC following the 
protocol described above. Both 
compounds were added to the 
diﬀerenaon media on the last 
four days of the diﬀerenaon pro-
tocol. Final concentraons used 
were 40μM for NCGC00160622-03 
and 10μM for NCGC00250218-01 
which were the IC50 tested in ﬁ-
broblasts. All WT derived neurons 
treated with the compounds pre-
sented cytotoxicity, detached from 
Fig28. Fibroblasts treated with diﬀerent concentraons of 
NCGC00250218-01 
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the plate and died before the treatment was complete. TS and TS L-HexA derived neu-
rons also presented cytotoxicity and died with 40μM of NCGC00160622-03 and were 
clearly damaged at 10 μM of NCGC00250218-01. Neuron slides which survived the 
treatment were ﬁxed with PFA and immunostained with Lamp2 and GM2, showing that 
the treatment with NCGC00250218-01 not only did not reduce the lysosome number 
and size, but increased it (Fig27). In order to conﬁrm the ﬁbroblast results achieved by 
our collaborators, an analysis with variable concentraons from 5 μM to 40 μM re-
vealed that the compounds used were also producing cytotoxicity without lysosome 
size or number reducon. This negave results might be due to an error while synthe-
zing the compounds, because the lysosome reducon eﬀect in ﬁbroblasts have been 
reproduced and observed in diﬀerent laboratories.   
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This PhD dissertaon describes the development of iPSC based disease models for Gau-
cher disease and Tay Sachs disease. The method of choice was the nucleofecon of a 
reprogramming construct into dermal ﬁbroblasts of GD and TS paents. The derived 
WT, GD and TS iPSC sasfy the standard quality requirements in the ﬁeld: they show 
ESC like morphology, express pluripotency markers (conﬁrmed by both immunostain-
ing and qPCR), and are able to diﬀerenate to all three germ layers both in vitro and by 
teratoma formaon in vivo. The TS iPSC have a normal karyotype, while the GD iPSC 
present an inversion on the chromosome 12, which did not aﬀect the phenotype for 
the purposes of the research as the results show. GD and TS iPSC were genotyped by 
sequencing to conﬁrm the presence of the original mutaons observed in the ﬁbro-
blasts, c.721 G>A and c.1448 T>C in GD and c.1260 G>C and IVS11+1 G>A in TS. Moreo-
ver, cell line origin veriﬁcaon was performed by STR analysis to conﬁrm GD and TS 
ﬁbroblasts as the original donor cells of the resulng GD and TS derived iPSC. GD and 
TS iPSC were diﬀerenated to the main cell types involved in each disease: macrophag-
es and neurons in GD and neurons in TS. In both cases, the diﬀerenated cells repro-
duce the disease hallmarks. In GD, reduced acid-b-glucosidase deﬁciency in both pro-
tein levels and enzymac acvity were observed in both neurons and macrophages. In 
TS,   an increase in the size and number of lysosomes was observed in TS iPSC derived 
neurons by TEM and immunostaining. Furthermore, the diﬀerenated cells were used 
to evaluate candidate drugs for the treatment of both diseases, providing a novel hu-
man based in vitro preclinical model. 
The classic method of reprogramming involves using retroviral vectors expressing a 
small number of ESC related transcripon factors, most frequently Oct4, Sox2, Klf4 and 
c-Myc, either cloned individually or as a polycistron (Gonzalez et al. 2009). In this work 
a linearized DNA fragment was used which included a CAG promoter driven 
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polycistronic cassee constuted by Oct4, Sox2, Klf4, c-Myc and GFP linked by 2A self-
cleaving pepdes. The cassee was ﬂanked by LoxP sites, allowing the excision and 
eliminaon of the cassee from the host genome by transient CRE recombinase ex-
pression once the reprogramming was complete. In this way, genomic inserons are 
minimized and if the reprogramming cassee does not silence spontaneously, it can be 
removed with CRE recombinase. When analyzing the inserons, 90% of the iPSC clones 
had only one transgene inseron. Some of the clones were able to silence the 
transgene expression aer 8-12 passages, but the rest did not and transgene excision 
was performed, eliminang problems derived from incomplete silencing or possible 
reacvaon of the transgene during diﬀerenaon.  
One factor to consider when deriving iPSC from paent ﬁbroblasts are possible delete-
rious eﬀects of the mutaon on the viability and physiology of the ﬁbroblasts to be re-
programmed. Previous reports have demonstrated the need for ectopic expression of 
the WT gene in mutated cells as a necessary prerequisite for successful reprogramming 
(Raya et al. 2009; Huang et al. 2011). There was no need to express wild type GBA and 
HEXA to reprogram GD and TS paent ﬁbroblasts. TS ﬁbroblasts gave rise to iPSC colo-
nies in the same me frame as WT ﬁbroblasts (4 weeks). However, in the case of GD,  
iPSC colonies took longer to develop (5-6 weeks), an observaon which has not been 
previously reported in published works on GD ﬁbroblast reprogramming (Park et al. 
2008; Panicker et al. 2012), suggesng that the diminished reprogramming ability could 
be due to a slower rate of ﬁbroblast cell division observed in GD ﬁbroblasts. Genec 
rescue was not needed in this case and we did not test whether the presence of WT 
GBA improved reprogramming eﬃciency or me-course of colony appearance.   Re-
gardless of the slower reprogramming process, GD iPSC were similar to WT iPSC by 
morphology, growth rate and expression of pluripotency markers as conﬁrmed by im-
munoﬂuorescence, microarray proﬁling and ﬂow cytometry analysis.  
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Several publicaons have reported the development of iPSC disease based models, 
establishing a convenient source of human disease speciﬁc cell types for dissecng 
mechanisms of pathogenesis and providing an intermediate level of tesng of pharma-
cological compounds between animal models and clinical trials (reviewed in Tiscornia 
et al. 2011; Onder et al. 2012). There are several advantages of iPSC disease models in 
contrast with other types of disease models such as primary ssue from paents or 
animal disease models. Primary cells from paents are hard to procure and are oen 
not the speciﬁc cell type involved in the pathology. Animal models, while having the 
advantage of studying the disease at the organismal level, suﬀer the disadvantage of 
species speciﬁc diﬀerences and paral reproducon of the human disease presenta-
on.  IPSC based models provide an ample source of the speciﬁc human cell type in-
volved in the disease. GD iPSC were diﬀerenated to macrophages, the main cell type 
involved in the systemic eﬀect of the disease, and neurons, damaged in type II and III 
forms of the disease. Meanwhile, as TS is mainly neurodegenerave, TS iPSC were 
diﬀerenated only to neurons.  
GD iPSC macrophage diﬀerenaon proved challenging, but succeeded in diﬀeren-
ang both WT and GD iPSC to macrophages by using a combinaon of the diﬀerena-
on protocols used by Raya (Raya et al. 2009) and Choi (Choi et al. 2011). The resulng 
macrophages showed expression of typical markers from the monocyte-macrophage 
lineage and proved to be funconal by phagocytosis of ﬂuorescent opsonized beads. 
GBA acvity was reduced in GD C21 macrophages compared to L-GBA 3-15 macrophag-
es as assessed by cytometry analysis. 
The neuronal subtypes aﬀected in GD are sll unclear, although the fact that neuro-
degeneraon takes in a number of regions and structures of the brain (Enquist et al. 
2007) suggests that more than one neuronal type is aﬀected. One neuronal cell type 
known to be aﬀected are the pyramidal neurons of the hippocampus. As diﬀerenaon 
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to this parcular cell type is not well worked out, diﬀerenaon of the GD iPSC to do-
paminergic neurons was chosen, for which robust and well characterized diﬀerena-
on protocols exist. Since in TS all neuronal types present membranous cytoplasmic 
bodies characterisc of the disease, diﬀerenaon them to the dopaminergic fate was 
also chosen.  
WT, GD, GD L-GBA, TS and TS L-HexA neurons derived from the corresponding iPSC us-
ing the dopaminergic diﬀerenaon protocol, resulted in heterogeneous populaons 
with high percentage of Tuj1+ neurons. Mature neuron markers as neuroﬁlament, syn-
apsin and NeuN were expressed in cell clusters. Neuronal precursor marker Map2+ was 
found in the majority of the neurons of the culture, indicang also heterogeneity on 
the developmental stage. All the cell lines produced TH+ dopaminergic neurons, experi-
encing variability between lines and between experiments which did not correlate with 
the presence or absence of GBA or HexA in the cells. GD derived neurons showed less 
GBA expression and, in consequence, the GBA acvity was lower than in WT and GD L-
GBA derived neurons. TS derived neurons also recapitulated the TS phenotype; more 
lysosomes were found on the TS derived neurons by immunoﬂuorescence and by TEM, 
mulllamelar membranous cytoplasmic bodies were detected in TS but not in WT. 
Given the high cost of developing pharmacological compounds for disease, being able 
to test potenal candidates early during the process on the relevant type of human cell 
is of great value. Human iPSC provide a pla	orm able to diﬀerenate to aﬀected cell 
types and test the potenal candidates before starng further preclinical studies and 
for showing it, GD and TS diﬀerenated neurons have been used for tesng novel phar-
macological compounds. 
Available treatments in GD are directed to alleviate the systemic symptoms of the dis-
ease, with no clinical beneﬁt for paents suﬀering from the neuronopathic symptoms 
of the disease. In this study, 2 new bicyclic nojirimycin analogues (Luan et al. 2009), 
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with high speciﬁcity for â-glucosidases, have been tested in the diﬀerenated neurons. 
With sub-inhibitory concentraons (30 μM), both compounds can increase protein and 
enzymac acvies several fold in diﬀerenated neuronal cultures derived from GD 
type II iPSC; furthermore, this eﬀect is also observed in WT cells, indicang that the 
eﬀect is not speciﬁc to the mutated form of the enzyme. The compound NOI-NJ has 
demonstrated to have good pharmacokinecs, can cross the cell membrane by diﬀu-
sion (Luan et al. 2010) and has the ability to enhance acid-b-glucosidase acvity in 
mouse ssues, including brain, as well as the lack of acute toxicity at high doses in nor-
mal mice (Luan et al. 2009), supporng their development as therapeuc candidates. 
While the manuscript describing the development of the GD iPSC model was being re-
viewed for publicaon an arcle was published describing the derivaon of iPSC from 
diﬀerent paents ﬁbroblasts with three diﬀerent genotypes of the disease (Panicker et 
al. 2012). In this work, iPSC were derived, characterized and diﬀerenated to neurons 
and macrophages. Furthermore the pharmacological chaperone Isofagomine and re-
combinant GBA were tested on the derived macrophages which showed paral or total 
recovery of the WT phenotype respecvely. These results were consistent with the al-
ready known eﬃcacies of both treatments in the clinic, underscoring the usefulness of 
a human cellular model for tesng potenal pharmacological candidates. Nevertheless, 
they did not present data of either treatment on neurons, even when Isofagomine has 
showed increased GBA protein and acvity in the brain of mice models of GD disease 
(Sun et al. 2011; Sun et al. 2012). Two previous publicaons in which GD iPSC were 
generated (Park et al. 2008) and diﬀerenated to dopaminergic neurons (Mazzulli et al. 
2011) did not use the system to evaluate therapeuc compounds. The present study is 
the ﬁrst to test chaperone candidates on GD type II derived neurons from its corre-
spondent iPSC, being complementary to the studies presented above.  
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Tay Sachs therapy is focused on supporve care and neither ERT nor SRT have reported 
beneﬁts in the clinic (Johnson et al. 1973; Maegawa et al. 2009; Shapiro et al. 2009). 
Along with the design and tesng of pharmacological chaperones for the á-subunit of 
the HexA enzyme, studies on the promoon of exocytosis for treang lysosomal stor-
age diseases have been made. It has been demonstrated that ä-tocopherol mediated 
exocytosis normalize the lysosome size in Niemann-Pick and Wolman diseases. Also, ä-
tocopherol shows a reducing eﬀect on the lysosome size of TS ﬁbroblasts (Xu et al. 
2012). In this study, ä-tocopherol and its analogue NCGC00250218-01 have been fur-
ther tested in neurons derived from TS iPSC. None of them was able to normalize the 
TS phenotype, moreover, diﬀerenated neurons showed high cytotoxicity at low con-
centraons of the compounds. In contrast with published reports and results obtained 
in other laboratories, cytotoxicity was observed in both iPSC derived neurons as well as 
ﬁbroblasts for both TS and WT cells. Furthermore, no clear reducon of the size of the 
lysosome was noceable in surviving cells. As cytotoxicity was occurring in both TS and 
WT and there was no reported evidence of cytotoxicity on ﬁbroblasts at high concen-
traons of ä-tocopherol, we hypothesize that an undetected problem occurred during 
the synthesis of the parcular batch of small molecules used. Further studies are re-
quired in order to conﬁrm or reject the preliminary data on neurons and ﬁbroblasts 
obtained in this study. 
GM2 degradaon pathways diﬀer in human and mouse, complicang the study of the 
pathology of the disease in mouse models. In humans there are 3 diseases caused by 
the malfuncon of this pathway:  Tay Sachs disease, in which the á-subunit of the HexA 
(áâ) enzyme is defecve; Sandhoﬀ disease, caused by mutaons in the HEXB gene (â-
subunit), aﬀecng both HexA (áâ) and HexB (ââ) enzymes; GM2 acvator deﬁciency 
aﬀects all the hexosaminidase enzymes. GM2 in humans can only be degraded by HexA; 
meanwhile, in mice, GM2 can be also degraded by sialidase, producing GA2 which will be 
further degraded by HexA and HexB (Gravel et al. 2001). Thus, mice models for TS can-
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not reproduce the observed phenotype of the disease in humans and for studying the 
eﬀect of the GM2 accumulaon the Sandhoﬀ mouse model is usually used. Recently an 
arcle has published the iPSC derivaon from a mouse model of Sandhoﬀ disease 
(Ogawa et al. 2013). They found impairment on the neuronal diﬀerenaon of the 
Sandhoﬀ iPSC which was rescued when â-subunit was restored, connecng the diﬀer-
enaon impairment to the GM2 accumulaon. In contrast, in the present study it was 
not detected any eﬀect of the TS mutaon on the diﬀerenaon capability of human 
TS iPSC to neurons, highlighng the lack of reliable models for the study of not only TS, 
but also the eﬀects that the GM2 accumulaon has on the GM2 gangliosidoses. 
In this study, it has been demonstrated the ulity of iPSC for disease modeling as a 
complementary approach to mouse modeling to advance the understanding of GD and 
TS diseases. Both models have been derived and characterized, probing that the princi-
pal hallmarks of the diseases are present. Also, it has been demonstrated their ulity to 
test and develop novel drugs for treatment. The present models will be able to be used 
for the study of the mechanisms of the disease, including metabolomics and tran-
scriptomics in order to uncover pathways aﬀected by the diseases. It would be of great 
value the development of iPSC panels covering the most common genotypes of the 
diseases, in order to evaluate the eﬀect and possible treatment for each mutaon. 
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Conclusions 
 
 
 
1. iPSC technology can be used for modeling monogenic diseases. 
2. Despite their genec defect, Gaucher and Tay Sachs diseases can be repro-
grammed, giving rise to full pluripotent iPSC. 
3. Gaucher iPSC can be diﬀerenated to typical aﬀected cell types by the disease 
such as dopaminergic neurons and macrophages and those recapitulate the 
reducon of GBA protein and lack of GBA acvity typical of the mutaons 
p.L444P and p.G202R of the GBA1 gene. 
4. GD iPSC can be used as a pla	orm for producing diﬀerenated neurons for 
tesng potenal drugs in preclinical studies. 
5. The bicyclic nojirimycin analogues NOI-NJ and 6S-ADBI-NJ increase GBA protein 
levels and enzymac acvity in neurons derived from GD type II iPSC, oﬀering a 
possible treatment for the neuronopathic forms of the disease. 
6. Tay Sachs iPSC can be diﬀerenated to dopaminergic neurons, recapitulang 
typical hallmarks of the disease as enlarged size of the lysosomes and the la-
mellar ultrastructures observed at TEM. 
7. TS iPCS can be used as a pla	orm for producing diﬀerenated neurons for 
tesng potenal drugs in preclinical studies. 
8. Although promising results have been published, further studies need to be 
developed with δ-tocopherol analogues to prove their eﬀecveness in reduc-
ing the size of the lysosomes in TS neurons without causing cytotoxicity. 
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Para comprender los múlples fenómenos observados en los seres vivos se han uliza-
do animales modelo como la mosca de la fruta, nemátodos, bacterias, levaduras, pez 
cebra, ratones e incluso mamíferos de mayor tamaño como cerdos, ovejas y primates. 
Estos modelos son representaciones simpliﬁcadas del fenómeno en estudio, especial-
mente úles cuando el modelo real no puede ser estudiado directamente por razones 
técnicas o écas como es el caso de los estudios de enfermedades humanas. 
Los ratones han sido usados para la mayoría de estudios biomédicos. Las ventajas de 
este modelo son amplias: pequeño, con una alta capacidad reproducva, relavamen-
te barato y fácil de mantener. Además, la ingeniería genéca desarrollada en las úl-
mas décadas del siglo 20 ha permido las modiﬁcaciones genécas necesarias para 
reproducir el genopo de enfermedades humanas en el ratón. El uso de animales mo-
delo permite un estudio a nivel de organismo, procurando un ambiente ﬁsiológico en 
el que los diferentes pos celulares y órganos interactúan. Sin embargo, hay diferen-
cias entre humanos y ratones que limitan la ﬁdelidad del ratón a la hora de reproducir, 
ya no sólo los fenopos clínicos de las enfermedades observados en los humanos, sino 
también los efectos de los fármacos ensayados pueden tener diferentes resultados 
(Wilson 1996; Odom et al. 2007; Perel et al. 2007). Para paliar esto, se han usado 
modelos celulares humanos con la ventaja de ofrecer acceso al ambiente real en el que 
se encuentra el defecto, pero perdiendo las ventajas que da el estudio in vivo. El 
culvo primario de células ha procurado información sobre la eología de las 
enfermedades, estudios del efecto de fármacos así como estudios sobre su toxicidad. 
El problema es obtener la candad suﬁciente de células para los estudios, además de 
que el acceso a los tejidos realmente afectados es complicado en casos de 
determinadas enfermedades como por ejemplo las neurodegeneravas.  
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Recientemente se han establecido líneas pluripotentes como las líneas de ESC 
derivadas de embriones preimplantacionales diagnoscados genécamente (Pickering 
et al. 2005; Mateizel et al. 2006) o con la derivación de iPSC de células primarias de 
pacientes (Tiscornia et al. 2011). Ambos modelos enen un alto potencial de 
crecimiento celular, ofreciendo una gran candad de material, además de poder ser 
diferenciados a los pos celulares más afectados en cada enfermedad. Las iPSC 
también son fáciles de derivar, tomando como población inicial células procedentes de 
biopsias de pacientes optando a la posibilidad de obtener un panel de iPSC de 
diferentes genopos de una misma enfermedad derivadas de disntos pacientes para 
poder estudiar los aspectos especíﬁcos de cada mutación. 
No hay un modelo perfecto, de manera que los conocimientos adquiridos de uno y de 
otro pueden ser complementados. Los modelos basados en células humanas pueden 
ser usados para estudiar los mecanismos de las enfermedades y como plataforma para 
probar fármacos y ayudar en su desarrollo. Por otro lado, los modelos animales pueden 
ser usados para obtener información sobre los aspectos sistémicos de la enfermedad y 
la farmacocinéca de los fármacos validados previamente en los modelos celulares, 
siempre teniendo en cuenta que la ﬁsiología entre el modelo animal y el humano es 
disnta. 
Así, en esta memoria se describe el desarrollo de modelos celulares de iPSC para dos 
enfermedades de almacenamiento lisosomal: la enfermedad de Gaucher y la 
enfermedad de Tay Sachs. 
Enfermedad de Gaucher 
La enfermedad de Gaucher es una enfermedad autosómica recesiva incluida en el 
grupo de enfermedades de almacenamiento lisosomal. Afecta a uno de cada 40000-
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60000 nacidos vivos en la población general y uno de cada 400-600 en la población 
judía ashkenazi. Gaucher está causada por mutaciones en el gen GBA1, localizado en 
Chr1q21, que codiﬁca para la enzima glucocerebrosidasa (GBA). La GBA es la encargada 
de catabolizar el sustrato glucosilceramida en ceramida y glucosa y su mal 
funcionamiento provoca la acumulación del sustrato en los lisosomas de macrófagos y 
neuronas principalmente. 
Tiene tres presentaciones clínicas atendiendo a la edad de presentación de los 
síntomas y a la presencia de afectación neurológica (Knudson et al. 1962): 
Tipo I: Forma no neuronopáca (OMIM #230800). Es la presentación más suave de la 
enfermedad en la que no hay  síntomas neurológicos, pero sí de carácter sistémico. La 
aparición de los síntomas se puede dar a cualquier edad, pero lo más habitual es su 
aparición en la edad adulta. 
Tipo II: Neuronopáca aguda (OMIM #230900). Es la forma menos frecuente de 
presentación de enfermedad (uno en cada 150000 nacidos vivos), pero también la más 
severa. La aparición de los síntomas neurológicos se da antes del sexto mes de vida y la 
progresión es rápida, derivando en la muerte del paciente antes de cumplir los tres 
años.  
Tipo III: Neuronopáca crónica (OMIM #2310000). Es una forma intermediaria entre el 
po I y el II. Los síntomas aparecen en la infancia o adolescencia con una afectación 
neurológica menos grave y con una progresión más lenta que la del po II, pero con 
una afectación visceral idénca al po I. 
La sintomatología de la enfermedad de Gaucher se trata mediante el uso de 
analgésicos, transfusiones de sangre y exrpación del bazo y parte del hígado. Por otro 
lado, la causa de la enfermedad, la acumulación de glucosilceramida, se trata mediante 
terapia de sustución enzimáca, terapia de reducción de sustrato o mediante 
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chaperonas farmacológicas. En la sustución enzimáca, se administra la enzima GBA 
al paciente, que es reconocida e incorporada por los macrófagos, sustuyendo al GBA 
endógeno mutado y elevando los niveles de acvidad de la GBA dentro de la célula 
(Beutler 2004). En la terapia de reducción de sustrato lo que se busca es reducir el 
sustrato de la GBA, la glucosilceramida, a través de la inhibición de la 
glucosiltransferasa por imino-azúcares como el N-butyldeoxynojirimycin (NB-DNJ) 
(Aerts et al. 2006). Ninguno de estos dos pos de terapia ha mostrado efecvidad en la 
sintomatología neurológica, de forma que sólo se usan con éxito en pacientes del po I 
o III. Por otro lado, las chaperonas farmacológicas son inhibidores de la GBA que al 
unirse de forma reversible con la enzima, estabilizan su estructura, evitando su 
degradación y promoviendo su transporte al lisosoma, donde el inhibidor se separa del 
enzima, dejándolo libre para que ejerza su función. Las chaperonas son análogos de los 
imino-azúcares usados en la terapia de reducción enzimáca y algunos de ellos, 
capaces de cruzar la barrera hematoencefálica, ofreciendo la posibilidad de tratar las 
formas neuronopácas (Benito et al. 2011). 
Los modelos en ratón desarrollados para el estudio de la enfermedad no resultaron ser 
del todo sasfactorios ya que, a pesar de que presentaban una baja acvidad GBA y 
acumulación de glucosilceramida en hígado y cerebro, los ratones morían 48 horas 
después de nacer (Tybulewicz et al. 1992; Liu et al. 1998). El único modelo de ratón 
creado capaz de recapitular la sintomatología neurológica (Enquist et al. 2007) lo hace 
por eliminación de GBA, no mimezando las mutaciones encontradas en humanos, 
siendo úl para el estudio de los efectos patológicos de la enfermedad en los disntos 
tejidos, pero no para ensayos de fármacos. 
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Enfermedad de Tay Sachs 
Tay Sachs es una enfermedad autosómica recesiva incluida en el grupo de 
enfermedades de almacenamiento lisosomales y más concretamente en el grupo de las 
gangliosidosis po GM2. Está causada por mutaciones en el gen HEXA, localizado en 
Chr15q23 y que codiﬁca para la subunidad α de la enzima heterodimérica β-
hexosaminidasa (HexA) que cataliza la degradación del gangliósido GM2. Fallos en HexA 
provocan la acumulación de GM2 en los lisosomas de células neuronales, interﬁriendo 
con la acvidad celular y causando degeneración neuronal. 
La enfermedad de Tay Sachs afecta a uno de cada 360000 nacidos en la población 
general y uno cada 2500-3600 en la población judía ashkenazi. La enfermedad ene 
tres formas de presentación de acuerdo a la edad en la que se presenta y la gravedad 
de los síntomas. En la forma infanl aguda, los síntomas (falta de respuesta antes 
esmulos externos, debilidad y pérdida de habilidades mentales y motoras) aparecen 
entre los 3 y 5 meses de vida y empeoran rápidamente, causando la muerte antes de 
los 4 años de edad. En la forma subaguda tardía que comienza con ataxia entre los 2 y 
los 10 años de edad, con un deterioro psicomotor progresivo. Los pacientes fallecen 
entre los 15 y los 20 años de edad. La forma crónica tardía puede aparecer en cualquier 
punto presentando gran variabilidad en las manifestaciones y su progresión, llegando a 
encontrar pacientes de avanzada edad (Gravel et al. 2001). 
Actualmente el tratamiento para la enfermedad de Tay Sachs se centra en cuidados 
paliavos. Se estudia la posibilidad de usar la terapia de sustución enzimáca, 
reducción de sustrato y chaperonas farmacológicas, sin embargo, a pesar de los 
esfuerzos, hasta el momento ninguna ha resultado efecva (von Specht et al. 1979; 
Maegawa et al. 2009; Shapiro et al. 2009; Clarke et al. 2011; Osher et al. 2011). Una 
nueva línea de invesgación en el tratamiento de la enfermedad es la esmulación de 
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la exocitosis de los lisosomas, con lo que se restaura el tamaño normal del lisosoma y 
se reduce la acumulación de GM2 (Klein et al. 2005; Medina et al. 2011; Xu et al. 2012) 
El metabolismo del GM2 es diferente en ratones y en humanos. En humanos, el GM2 sólo 
puede ser degradado por la enzima HexA, sin embargo en ratones puede serlo por la 
HexA y por la acción de la sialidasa, haciendo que los ratones KO para HEXA no 
desarrollen el fenopo descrito en humanos. Para los estudios del efecto de la 
acumulación del GM2 en el tejido neuronal se usan ratones deﬁcientes en HEXB 
(enfermedad de Sandhoﬀ), que sí acumulan GM2 en neuronas, pero por el contrario, no 
pueden ser ulizados para probar fármacos especíﬁcos para Tay Sachs. 
Resultados 
En este trabajo se presenta la derivación de células madre pluripotentes inducidas 
(iPSC) a parr de ﬁbroblastos de pacientes tanto de Gaucher como de Tay Sachs. Las 
iPSC se generaron introduciendo un fragmento lineal de ADN que contenía los factores 
de reprogramación Oct4, Sox2, Klf4 y c-Myc junto con GFP como marcador, todos 
unidos por secuencias p2A y bajo el control del promotor CAG. Este casete de 
expresión está ﬂanqueado por secuencias LoxP, permiendo su escisión por expresión 
de la recombinasa CRE una vez completada la reprogramación. 
Las iPSC de Gaucher y Tay Sachs presentan una morfología caracterísca de células 
madre embrionarias, junto con la expresión de marcadores de pluripotencia analizados 
por inmunoﬂuorescencia y PCR cuantava. Además, las iPSC generadas son capaces 
de diferenciarse in vivo e in vitro a las tres capas germinales del embrión: endodermo, 
ectodermo y mesodermo, cumpliendo así con los estándares de calidad exigidos. El 
análisis del cariopo es normal en las iPSC de Tay Sachs, pero revela una inversión en el 
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cromosoma 12 en las iPSC de Gaucher que no afecta en la diferenciación ni en el 
fenopo de la enfermedad mostrado.  
El fenopo de la enfermedad de Gaucher fue comprobado en ﬁbroblastos y iPSC de 
Gaucher con ensayos enzimácos que probaban que tanto los ﬁbroblastos como las 
iPSC derivadas de ellos tenían una acvidad de GBA menor a la de las correspondientes 
FigR-1. Análisis de pluripotencia de las iPSC derivadas de ﬁbroblastos WT y de pacientes de TS y GD 
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WT; además, el western blot reveló que la candad de enzima GBA en las iPSC de 
Gaucher era menor que en las WT.  
Las GD iPSC fueron diferenciadas a los pos celulares más afectados por la 
enfermedad: macrófagos y neuronas. Se obtuvieron macrófagos (CD11b+, CD14+, 
CD33+ y CD163+) funcionales capaces de fagocitar micro parculas ﬂuorescentes 
opsonizadas. También se midieron sus niveles de GBA y su acvidad por citometría de 
ﬂujo, demostrando que los macrófagos recapitulaban el fenopo de la enfermedad. 
Por otro lado, las iPSC fueron diferenciadas a neuronas dopaminérgicas (TH) que 
expresaban marcadores neuronales picos (Tuj1) junto con marcadores de diferentes 
estadíos de maduración (Map2, neuroﬁlament, synapsin y NeuN). Estas neuronas 
mostraron menor candad de enzima GBA en los western blots, además de una menor 
acvidad enzimáca de GBA, de acuerdo con el fenopo de la enfermedad. 
FigR-2. Panel de los diferentes estadíos de la diferenciación a neuronas dopaminérgicas 
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Ninguno de los tratamientos usados hasta ahora para la enfermedad de Gaucher ha 
mostrado tener efecto en el sistema nervioso. Sin embargo, recientemente se ha visto 
que unas chaperonas farmacológicas análogas a la nojirimicina bicíclica con alta 
especiﬁcidad por la GBA, pueden cruzar la barrera hematoencefálica, llegando al 
cerebro (Luan et al. 2009). Así, las neuronas derivadas de GD C21 iPSC fueron usadas 
para probar estos análogos. Se probaron dos compuestos, NOI-NJ y 6S-ADBI-NJ, que 
ofrecían un aumento en la acvidad enzimáca de la GBA en ﬁbroblastos de Gaucher 
sin causar un efecto negavo en los ﬁbroblastos control. Ambos compuestos fueron 
añadidos al medio de culvo en los 4 úlmos días de diferenciación neuronal. Las 
neuronas obtenidas se lisaron y se hicieron mediciones de la acvidad enzimáca del 
GBA, mostrando una mayor acvidad (3-4 veces mayor) aquellas neuronas de Gaucher 
que habían sido tratadas con los 
compuestos respecto de las no 
tratadas. El western blot también 
mostró una mayor candad de 
proteína GBA en los extractos de 
neuronas que habían sido tratadas 
con los compuestos respecto de las 
que no lo habían sido. Estos 
resultados sugieren que los 
análogos de la nojirimicina bicíclica 
incrementan la candad de proteína 
GBA y por tanto, elevan la acvidad 
enzimáca. 
Para caracterizar el fenopo de las TS iPSC se analizó la acvidad de la HexA, 
mostrando una clara reducción de la acvidad de HexA en los ﬁbroblastos y en las iPSC 
de Tay Sachs respecto de los ﬁbroblastos e iPSC WT. Las iPSC se diferenciaron a 
FigR-3. Neuronas derivadas de iPSC WT, GD y GD rescatadas y 
tratadas con NOI-NJ y 6S-ADBI-NJ 
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neuronas, ya que la patología de TS se da casi exclusivamente en el sistema nervioso. 
Se ulizó el mismo protocolo que con las GD iPSC, obteniendo neuronas que 
presentaban caracteríscas picas de neuronas de pacientes de TS tales como el 
agrandamiento y aumento de número de lisosomas, observable por 
inmunoﬂuorescencia (Lamp2, GM2); y la aparición de cuerpos laminares en el 
citoplasma de las neuronas, analizado con el microscopio electrónico de transmisión. 
FigR-4. Neuronas WT, TS Y TS corregidas observadas al microscopio confocal (A) y con el microscopio electrónico de 
transmisión (B). En ambas se puede apreciar un aumento del tamaño y candad de los lisosomas en TS respecto de WT 
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Al no haber encontrado en estrategias de tratamiento tales como la sustución 
enzimáca o la reducción de sustrato un tratamiento eﬁcaz frente a los síntomas de 
Tay Sachs, otras estrategias están siendo estudiadas. Se ha publicado un estudio en el 
que el δ-tocoferol favorece la exocitosis de lisosomas en las enfermedades de Niemann 
Pick y Wolman, normalizando en ellas la candad y el tamaño de los lisosomas. El δ-
tocoferol puede ser ulizado en las enfermedades de almacenamiento lisosomal 
incluyendo TS. Así, las neuronas derivadas de TS iPSC se usaron como plataforma para 
FigR-5. Neuronas derivadas de WT, TS y TS corregidas tratadas con 10uM de NCGC00250218-01 
  100 
 
probar el efecto del δ-tocoferol y un análogo. Ambos compuestos se añadieron al 
medio de diferenciación en los úlmos 4 días del protocolo. A pesar de los resultados 
obtenidos anteriormente, ambos compuestos mostraron citotoxicidad en neuronas 
tanto WT como TS, sin observar una normalización en el tamaño del lisosoma en las 
células supervivientes. Esta citotoxicidad también fue observada en ﬁbroblastos WT y 
TS. Estos resultados contrastan con los resultados publicados, pudiendo deberse a una 
síntesis incorrecta de los compuestos. Más experimentos han de llevarse a cabo para 
poder constatar los efectos, posivos o negavos, de los compuestos probados. 
En esta memoria se ha descrito la derivación de iPSC para “modelar” las enfermedades 
de Gaucher y Tay Sachs. Las iPSC se consiguieron mediante la nucleofección de un 
vector de reprogramación en ﬁbroblastos procedentes de pacientes de GD y TS. Estas 
iPSC cumplen los requisitos de calidad picos (morfología de ESC, expresión de 
marcadores de pluripotencia y habilidad de diferenciarse in vivo e in vitro). Mientras el 
cariopo es normal en las iPSC de TS, presenta una inversión en el cromosoma 12 en 
las iPSC de Gaucher que no interﬁere con la diferenciación ni con el fenopo pico 
mostrado en la enfermedad. Las iPSC generadas fueron diferenciadas a los pos 
celulares más afectados por las enfermedades, neuronas en TS y neuronas y 
macrófagos en GD. Las células diferenciadas reproducen caracteríscas picas de las 
respecvas enfermedades. En el caso de la enfermedad de Gaucher, tanto en neuronas 
como en macrófagos se pudo observar una disminución en la candad de enzima GBA 
así como una deﬁciencia en los niveles de acvidad del enzima. En Tay Sachs, las 
neuronas mostraban un aumento en el tamaño y la candad de lisosomas que se pudo 
analizar por inmunoﬂuorescencia, marcando Lamp2 (marcador de lisosomas) y GM2, y 
por microscopía electrónica de transmisión. Las neuronas diferenciadas tanto en 
Gaucher como en Tay Sachs fueron ulizadas para evaluar posibles fármacos para el 
tratamiento de las enfermedades, pudiendo ser usadas como un modelo para hacer 
estudios preclínicos in vitro.  
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